###################################################################################################################################################################
#Enrichment results using 'Biological Process from Gene Ontology (GO)', created by dcGO Enrichment at 22/08/2016 13:01:18 (day/month/year hour:min:sec)
#Citation: Fang H, Gough J. (2012) dcGO: database of domain-centric ontologies on functions, phenotypes, diseases and more. Nucleic Acids Res (PubMed ID: 23161684)
###################################################################################################################################################################
#
#'GroupID' column: group id (by default 'Group' for single group);
#'GO ID' column: the identifier of ontological terms;
#'GO term' column: the name of ontological terms;
#'xxxx (four levels)' column: term specificity (only appear when using slim version of the ontology; 1 for highly general, 2 for general, 3 for specific, and 4 for highly specific);
#'Z-score' column: Z-score being calculated based on hypergeometric distribution;
#'P-value' column: P-value being calculated based on hypergeometric distribution;
#'FDR' column: FDR used to assess the statistical significance of term enrichments;
#'#Domains (Overlaps|Group|Term|Background)' column: the number of domains, i.e., 'Overlaps' for the number of domains in the input group but also being annotated by the term; 'Group' for the number of domains in the input group (also annotatable by the ontology); 'Term' for the number of domains being annotated by the term; 'Backgroud' for the number of domains that are annotatable by the ontology.
#'Annotated domains' column: a list of semicolon-separated domains in the input group but also being annotated by the term.
#
GroupID	GO ID	GO term	PFAM slim (four levels)	Z-score	P-value	FDR	#Domains (Overlaps|Group|Term|Background)	Annotated domains
Group	GO:0023051	regulation of signaling	1	12.73	2.70e-27	2.27e-24	93|240|441|3527	PF00014;PF00019;PF00027;PF00028;PF00040;PF00041;PF00049;PF00054;PF00057;PF00071;PF00090;PF00093;PF00096;PF00102;PF00122;PF00130;PF00169;PF00179;PF00240;PF00249;PF00341;PF00388;PF00397;PF00400;PF00435;PF00452;PF00514;PF00581;PF00594;PF00610;PF00611;PF00612;PF00618;PF00621;PF00625;PF00640;PF00651;PF00683;PF00688;PF00689;PF00690;PF00702;PF00757;PF00778;PF00780;PF00786;PF00969;PF01030;PF01064;PF01369;PF01391;PF01403;PF01404;PF01417;PF01437;PF01448;PF01485;PF01585;PF01699;PF01753;PF01833;PF01843;PF02037;PF02145;PF02148;PF02177;PF02210;PF02214;PF02377;PF02825;PF02931;PF03165;PF04055;PF06920;PF07525;PF07645;PF07653;PF07679;PF09279;PF09324;PF10409;PF12763;PF12783;PF12796;PF12924;PF13414;PF13499;PF13716;PF13855;PF13857;PF13920;PF14324;PF14429
Group	GO:0006928	cellular component movement	1	12.99	4.58e-26	1.93e-23	74|240|296|3527	PF00014;PF00019;PF00028;PF00041;PF00045;PF00052;PF00053;PF00054;PF00055;PF00057;PF00071;PF00096;PF00102;PF00130;PF00169;PF00225;PF00226;PF00241;PF00341;PF00388;PF00397;PF00400;PF00413;PF00435;PF00594;PF00611;PF00612;PF00618;PF00621;PF00640;PF00684;PF00688;PF00757;PF00778;PF00786;PF00989;PF01030;PF01064;PF01217;PF01403;PF01404;PF01437;PF01462;PF01833;PF01843;PF02148;PF02177;PF02181;PF02210;PF02214;PF03133;PF03607;PF06297;PF06367;PF06371;PF06920;PF07645;PF07653;PF07679;PF07719;PF07728;PF08393;PF08447;PF09279;PF10409;PF12348;PF12774;PF12775;PF12780;PF12924;PF13414;PF13499;PF13855;PF14429
Group	GO:0048519	negative regulation of biological process	1	11.63	1.48e-25	4.15e-23	115|240|681|3527	PF00019;PF00023;PF00028;PF00041;PF00049;PF00057;PF00071;PF00076;PF00090;PF00093;PF00096;PF00098;PF00102;PF00106;PF00122;PF00125;PF00130;PF00134;PF00169;PF00179;PF00225;PF00226;PF00240;PF00241;PF00249;PF00254;PF00341;PF00350;PF00388;PF00389;PF00397;PF00400;PF00435;PF00452;PF00514;PF00581;PF00594;PF00611;PF00621;PF00622;PF00625;PF00640;PF00643;PF00651;PF00683;PF00688;PF00689;PF00690;PF00702;PF00757;PF00778;PF00780;PF00786;PF00789;PF00969;PF01030;PF01064;PF01335;PF01391;PF01403;PF01404;PF01417;PF01448;PF01462;PF01477;PF01585;PF01699;PF01753;PF01833;PF01909;PF02037;PF02145;PF02148;PF02177;PF02181;PF02201;PF02210;PF02214;PF02709;PF02826;PF02931;PF03165;PF04055;PF05773;PF06297;PF07525;PF07645;PF07653;PF07679;PF07719;PF08210;PF08246;PF09279;PF10277;PF10409;PF10421;PF12348;PF12697;PF12763;PF12796;PF12906;PF12924;PF12947;PF13414;PF13415;PF13499;PF13638;PF13716;PF13733;PF13765;PF13854;PF13855;PF13857;PF13920;PF14324
Group	GO:0048583	regulation of response to stimulus	1	11.62	5.22e-24	1.10e-21	95|240|503|3527	PF00014;PF00019;PF00023;PF00027;PF00028;PF00040;PF00041;PF00049;PF00057;PF00071;PF00090;PF00093;PF00096;PF00102;PF00122;PF00130;PF00169;PF00179;PF00240;PF00249;PF00341;PF00388;PF00397;PF00400;PF00452;PF00514;PF00581;PF00594;PF00610;PF00611;PF00612;PF00618;PF00621;PF00625;PF00640;PF00651;PF00683;PF00688;PF00689;PF00690;PF00702;PF00757;PF00778;PF00780;PF00786;PF00969;PF01030;PF01064;PF01217;PF01369;PF01391;PF01403;PF01404;PF01417;PF01421;PF01437;PF01448;PF01462;PF01476;PF01485;PF01585;PF01753;PF01833;PF01843;PF02037;PF02145;PF02148;PF02177;PF02210;PF02214;PF02377;PF02825;PF02931;PF03165;PF04055;PF06920;PF07525;PF07534;PF07645;PF07653;PF07679;PF08246;PF09279;PF10409;PF12763;PF12796;PF12924;PF13414;PF13499;PF13716;PF13855;PF13857;PF13920;PF14324;PF14429
Group	GO:0030030	cell projection organization	1	12.14	1.45e-22	1.84e-20	63|240|246|3527	PF00014;PF00019;PF00023;PF00025;PF00028;PF00041;PF00052;PF00053;PF00054;PF00055;PF00071;PF00090;PF00096;PF00102;PF00130;PF00169;PF00225;PF00341;PF00397;PF00400;PF00415;PF00435;PF00514;PF00581;PF00610;PF00611;PF00612;PF00618;PF00621;PF00625;PF00640;PF00651;PF00688;PF00757;PF00778;PF00780;PF00786;PF01030;PF01064;PF01391;PF01403;PF01404;PF01437;PF01462;PF01833;PF02148;PF02177;PF02210;PF02377;PF03133;PF03165;PF03607;PF07645;PF07653;PF07679;PF07719;PF12348;PF12796;PF12924;PF13414;PF13716;PF13855;PF13857
Group	GO:0040011	locomotion	1	11.69	1.53e-22	1.84e-20	75|240|342|3527	PF00014;PF00019;PF00028;PF00041;PF00045;PF00052;PF00053;PF00054;PF00055;PF00057;PF00071;PF00090;PF00096;PF00098;PF00102;PF00130;PF00169;PF00225;PF00226;PF00241;PF00341;PF00397;PF00413;PF00435;PF00514;PF00594;PF00611;PF00612;PF00618;PF00621;PF00625;PF00640;PF00651;PF00684;PF00688;PF00757;PF00778;PF00780;PF00786;PF01030;PF01064;PF01391;PF01403;PF01404;PF01437;PF01462;PF01833;PF02145;PF02148;PF02177;PF02210;PF02214;PF02931;PF03165;PF03607;PF06297;PF06367;PF06371;PF06920;PF07645;PF07653;PF07679;PF07728;PF08393;PF08447;PF10409;PF12348;PF12774;PF12775;PF12780;PF12924;PF13414;PF13426;PF13855;PF14429
Group	GO:0048518	positive regulation of biological process	1	10.86	1.32e-22	1.84e-20	109|240|667|3527	PF00014;PF00019;PF00023;PF00025;PF00027;PF00040;PF00041;PF00049;PF00053;PF00054;PF00055;PF00057;PF00071;PF00076;PF00090;PF00093;PF00096;PF00098;PF00102;PF00122;PF00125;PF00130;PF00133;PF00134;PF00169;PF00179;PF00240;PF00241;PF00249;PF00341;PF00388;PF00397;PF00400;PF00435;PF00452;PF00514;PF00594;PF00611;PF00612;PF00618;PF00621;PF00625;PF00640;PF00643;PF00651;PF00688;PF00689;PF00690;PF00702;PF00757;PF00778;PF00780;PF00786;PF00969;PF00989;PF01030;PF01064;PF01335;PF01391;PF01403;PF01404;PF01417;PF01437;PF01448;PF01462;PF01476;PF01485;PF01585;PF01699;PF01833;PF02037;PF02177;PF02181;PF02210;PF02825;PF02845;PF02931;PF03165;PF04055;PF04144;PF05790;PF06367;PF06371;PF07525;PF07534;PF07645;PF07653;PF07679;PF07719;PF08210;PF08246;PF08447;PF09279;PF09816;PF10409;PF11717;PF12171;PF12697;PF12756;PF12763;PF12796;PF12924;PF13091;PF13414;PF13499;PF13716;PF13855;PF13920;PF14324
Group	GO:0032879	regulation of localization	1	11.76	1.87e-22	1.97e-20	72|240|318|3527	PF00019;PF00023;PF00027;PF00040;PF00041;PF00045;PF00049;PF00055;PF00071;PF00076;PF00090;PF00093;PF00098;PF00102;PF00122;PF00130;PF00169;PF00225;PF00254;PF00341;PF00388;PF00397;PF00400;PF00413;PF00435;PF00452;PF00514;PF00594;PF00610;PF00611;PF00612;PF00618;PF00622;PF00625;PF00688;PF00689;PF00690;PF00702;PF00757;PF00778;PF00969;PF01030;PF01064;PF01217;PF01391;PF01403;PF01437;PF01833;PF01843;PF02145;PF02210;PF02214;PF02931;PF04055;PF04144;PF04810;PF07645;PF07653;PF07679;PF08246;PF09279;PF10409;PF12697;PF12796;PF13091;PF13426;PF13499;PF13716;PF13765;PF13855;PF13903;PF13920
Group	GO:0007399	nervous system development	1	11.42	2.64e-22	2.47e-20	81|240|397|3527	PF00014;PF00019;PF00023;PF00025;PF00028;PF00041;PF00049;PF00052;PF00053;PF00054;PF00055;PF00057;PF00071;PF00090;PF00096;PF00102;PF00122;PF00130;PF00169;PF00225;PF00249;PF00254;PF00341;PF00397;PF00400;PF00415;PF00435;PF00452;PF00514;PF00610;PF00611;PF00612;PF00618;PF00621;PF00625;PF00640;PF00651;PF00688;PF00690;PF00702;PF00757;PF00778;PF00780;PF00786;PF01030;PF01064;PF01369;PF01391;PF01403;PF01404;PF01421;PF01437;PF01462;PF01833;PF02023;PF02145;PF02148;PF02177;PF02181;PF02210;PF02377;PF02931;PF03165;PF03607;PF06367;PF06371;PF07525;PF07645;PF07653;PF07679;PF10409;PF12348;PF12796;PF12924;PF13385;PF13414;PF13716;PF13855;PF13857;PF13903;PF14324
Group	GO:0051128	regulation of cellular component organization	1	11.51	7.05e-22	5.40e-20	73|240|333|3527	PF00019;PF00025;PF00028;PF00041;PF00049;PF00071;PF00096;PF00130;PF00134;PF00169;PF00179;PF00225;PF00226;PF00241;PF00249;PF00254;PF00341;PF00397;PF00400;PF00435;PF00452;PF00514;PF00594;PF00610;PF00611;PF00612;PF00618;PF00621;PF00622;PF00625;PF00640;PF00643;PF00651;PF00688;PF00757;PF00780;PF00786;PF01030;PF01064;PF01391;PF01403;PF01404;PF01437;PF01462;PF01833;PF01843;PF02037;PF02145;PF02148;PF02181;PF02210;PF02893;PF02931;PF03165;PF06367;PF06371;PF07645;PF07653;PF07679;PF07707;PF07719;PF08210;PF10409;PF12348;PF12796;PF12895;PF12906;PF13091;PF13414;PF13499;PF13765;PF13855;PF13920
Group	GO:0051239	regulation of multicellular organismal process	1	11.15	6.62e-22	5.40e-20	86|240|448|3527	PF00014;PF00019;PF00023;PF00025;PF00027;PF00028;PF00041;PF00049;PF00054;PF00071;PF00076;PF00090;PF00093;PF00096;PF00102;PF00122;PF00125;PF00130;PF00169;PF00225;PF00240;PF00249;PF00254;PF00341;PF00400;PF00435;PF00452;PF00514;PF00594;PF00610;PF00611;PF00612;PF00618;PF00621;PF00622;PF00640;PF00643;PF00651;PF00688;PF00689;PF00690;PF00702;PF00778;PF00780;PF00786;PF00969;PF01064;PF01391;PF01403;PF01404;PF01417;PF01437;PF01462;PF01699;PF01753;PF01833;PF01843;PF02023;PF02037;PF02177;PF02181;PF02210;PF02214;PF02377;PF02931;PF03165;PF04055;PF04144;PF06367;PF06371;PF07525;PF07645;PF07653;PF07679;PF08246;PF10409;PF12763;PF12796;PF12924;PF12947;PF13414;PF13426;PF13716;PF13765;PF13855;PF13857
Group	GO:0032990	cell part morphogenesis	1	12.07	1.06e-21	7.43e-20	57|240|210|3527	PF00014;PF00023;PF00025;PF00028;PF00041;PF00052;PF00053;PF00054;PF00055;PF00090;PF00096;PF00102;PF00130;PF00169;PF00225;PF00397;PF00400;PF00415;PF00435;PF00514;PF00581;PF00611;PF00621;PF00625;PF00651;PF00688;PF00757;PF00778;PF00780;PF00786;PF01030;PF01064;PF01391;PF01403;PF01404;PF01437;PF01462;PF01833;PF02148;PF02177;PF02210;PF02377;PF02893;PF03133;PF03165;PF03607;PF07645;PF07653;PF07679;PF07719;PF12348;PF12796;PF12924;PF13414;PF13716;PF13855;PF13857
Group	GO:0051674	localization of cell	1	11.78	3.21e-21	2.08e-19	59|240|229|3527	PF00019;PF00028;PF00041;PF00045;PF00052;PF00053;PF00054;PF00055;PF00057;PF00071;PF00096;PF00102;PF00130;PF00226;PF00241;PF00341;PF00397;PF00413;PF00435;PF00514;PF00594;PF00611;PF00612;PF00618;PF00621;PF00640;PF00684;PF00688;PF00757;PF00778;PF01030;PF01064;PF01403;PF01404;PF01437;PF01462;PF01833;PF02148;PF02210;PF02214;PF03607;PF06297;PF06367;PF06371;PF06920;PF07645;PF07653;PF07679;PF07728;PF08393;PF08447;PF10409;PF12348;PF12774;PF12775;PF12780;PF13414;PF13855;PF14429
Group	GO:0051641	cellular localization	1	10.67	9.89e-21	5.95e-19	89|240|494|3527	PF00014;PF00019;PF00023;PF00025;PF00027;PF00041;PF00053;PF00054;PF00071;PF00076;PF00122;PF00130;PF00153;PF00169;PF00179;PF00225;PF00226;PF00240;PF00341;PF00350;PF00388;PF00397;PF00400;PF00435;PF00452;PF00514;PF00581;PF00610;PF00611;PF00612;PF00618;PF00622;PF00625;PF00640;PF00651;PF00683;PF00688;PF00689;PF00690;PF00702;PF00780;PF00786;PF00989;PF01217;PF01369;PF01391;PF01403;PF01417;PF01465;PF01843;PF02064;PF02145;PF02177;PF02181;PF02210;PF02828;PF02893;PF02931;PF03810;PF04144;PF04695;PF04810;PF07645;PF07653;PF07679;PF07707;PF07719;PF07728;PF08389;PF08393;PF08447;PF09279;PF09324;PF12171;PF12348;PF12756;PF12763;PF12774;PF12775;PF12780;PF12783;PF12796;PF12924;PF13246;PF13385;PF13414;PF13499;PF13855;PF13920
Group	GO:0065008	regulation of biological quality	1	10.36	1.32e-20	7.44e-19	102|240|628|3527	PF00014;PF00019;PF00023;PF00025;PF00027;PF00028;PF00041;PF00049;PF00057;PF00071;PF00076;PF00082;PF00093;PF00096;PF00102;PF00106;PF00122;PF00130;PF00153;PF00169;PF00225;PF00240;PF00241;PF00249;PF00254;PF00341;PF00388;PF00397;PF00400;PF00435;PF00452;PF00514;PF00583;PF00594;PF00610;PF00611;PF00612;PF00618;PF00621;PF00622;PF00625;PF00640;PF00643;PF00651;PF00683;PF00688;PF00689;PF00690;PF00702;PF00780;PF00786;PF01064;PF01217;PF01336;PF01391;PF01403;PF01404;PF01417;PF01421;PF01437;PF01462;PF01477;PF01496;PF01553;PF01699;PF01843;PF02023;PF02037;PF02145;PF02148;PF02177;PF02181;PF02210;PF02214;PF02225;PF02828;PF02893;PF02931;PF03165;PF06367;PF06371;PF06920;PF07645;PF07653;PF07679;PF07707;PF08246;PF09279;PF10409;PF12171;PF12348;PF12756;PF12763;PF12796;PF12924;PF13246;PF13499;PF13716;PF13855;PF13857;PF13903;PF14429
Group	GO:0009790	embryo development	1	11.20	1.61e-20	8.47e-19	67|240|299|3527	PF00019;PF00025;PF00028;PF00041;PF00052;PF00053;PF00054;PF00057;PF00071;PF00076;PF00093;PF00096;PF00102;PF00122;PF00125;PF00130;PF00133;PF00134;PF00169;PF00225;PF00249;PF00341;PF00388;PF00400;PF00435;PF00452;PF00514;PF00583;PF00610;PF00612;PF00621;PF00622;PF00625;PF00640;PF00651;PF00688;PF00689;PF00690;PF00702;PF00757;PF00778;PF00786;PF00989;PF01030;PF01064;PF01391;PF01403;PF01417;PF01448;PF01843;PF02145;PF02210;PF02377;PF02828;PF03165;PF06297;PF07525;PF07645;PF07653;PF07679;PF08447;PF09279;PF12796;PF13091;PF13414;PF13499;PF13857
Group	GO:0007154	cell communication	1	10.10	4.21e-20	2.08e-18	107|240|691|3527	PF00014;PF00019;PF00023;PF00025;PF00027;PF00028;PF00041;PF00049;PF00057;PF00071;PF00076;PF00082;PF00090;PF00096;PF00098;PF00102;PF00106;PF00122;PF00130;PF00134;PF00169;PF00179;PF00225;PF00226;PF00240;PF00249;PF00341;PF00388;PF00397;PF00400;PF00435;PF00452;PF00514;PF00581;PF00594;PF00610;PF00611;PF00612;PF00618;PF00621;PF00622;PF00625;PF00640;PF00643;PF00651;PF00683;PF00684;PF00688;PF00689;PF00690;PF00702;PF00757;PF00778;PF00780;PF00786;PF00899;PF00969;PF00989;PF01030;PF01064;PF01179;PF01217;PF01370;PF01391;PF01403;PF01404;PF01417;PF01421;PF01437;PF01462;PF01465;PF01833;PF01843;PF02023;PF02140;PF02145;PF02177;PF02210;PF02214;PF02377;PF02759;PF02825;PF02828;PF02931;PF03165;PF05773;PF05790;PF07525;PF07645;PF07653;PF07679;PF07707;PF07719;PF08246;PF08447;PF09279;PF10277;PF10409;PF12763;PF12796;PF12874;PF12924;PF13426;PF13499;PF13716;PF13855;PF13857
Group	GO:0009605	response to external stimulus	1	10.91	4.94e-20	2.31e-18	70|240|330|3527	PF00014;PF00019;PF00023;PF00027;PF00028;PF00041;PF00052;PF00053;PF00054;PF00055;PF00071;PF00076;PF00082;PF00090;PF00096;PF00098;PF00102;PF00122;PF00225;PF00341;PF00397;PF00400;PF00435;PF00594;PF00612;PF00618;PF00621;PF00622;PF00625;PF00640;PF00651;PF00688;PF00689;PF00690;PF00702;PF00778;PF00780;PF00786;PF00899;PF00969;PF01064;PF01179;PF01391;PF01403;PF01404;PF01437;PF01462;PF01833;PF02145;PF02148;PF02177;PF02210;PF02931;PF03165;PF05773;PF06920;PF07645;PF07679;PF08246;PF10409;PF12348;PF12796;PF12924;PF13091;PF13426;PF13499;PF13765;PF13855;PF13857;PF14429
Group	GO:0000902	cell morphogenesis	1	11.15	5.97e-20	2.65e-18	62|240|265|3527	PF00014;PF00019;PF00023;PF00025;PF00028;PF00041;PF00052;PF00053;PF00054;PF00055;PF00071;PF00090;PF00096;PF00102;PF00130;PF00169;PF00225;PF00249;PF00397;PF00400;PF00415;PF00435;PF00514;PF00581;PF00611;PF00621;PF00625;PF00640;PF00651;PF00688;PF00757;PF00778;PF00780;PF00786;PF01030;PF01064;PF01391;PF01403;PF01404;PF01437;PF01462;PF01833;PF01843;PF02148;PF02177;PF02210;PF02377;PF03133;PF03165;PF03607;PF06920;PF07645;PF07653;PF07679;PF07719;PF12348;PF12796;PF12924;PF13414;PF13716;PF13855;PF13857
Group	GO:0065009	regulation of molecular function	1	10.60	1.02e-19	4.19e-18	77|240|396|3527	PF00014;PF00019;PF00023;PF00025;PF00027;PF00028;PF00041;PF00049;PF00057;PF00071;PF00076;PF00090;PF00102;PF00130;PF00134;PF00169;PF00179;PF00226;PF00240;PF00254;PF00341;PF00388;PF00397;PF00400;PF00415;PF00452;PF00514;PF00581;PF00594;PF00610;PF00611;PF00612;PF00618;PF00621;PF00622;PF00625;PF00640;PF00643;PF00688;PF00757;PF00778;PF00780;PF00786;PF00899;PF01335;PF01391;PF01403;PF01404;PF01437;PF01585;PF01909;PF02145;PF02148;PF02177;PF02210;PF02377;PF02931;PF03165;PF04055;PF06920;PF07258;PF07525;PF07645;PF07653;PF07679;PF08246;PF09279;PF09324;PF10421;PF12796;PF12924;PF13499;PF13716;PF13855;PF13903;PF13920;PF14429
Group	GO:0043412	macromolecule modification	1	10.14	1.05e-19	4.19e-18	98|240|602|3527	PF00014;PF00019;PF00023;PF00025;PF00027;PF00041;PF00049;PF00054;PF00071;PF00076;PF00102;PF00130;PF00134;PF00169;PF00179;PF00225;PF00240;PF00249;PF00254;PF00341;PF00383;PF00397;PF00400;PF00415;PF00514;PF00581;PF00583;PF00594;PF00611;PF00622;PF00640;PF00643;PF00651;PF00688;PF00757;PF00780;PF00786;PF00899;PF00989;PF01030;PF01064;PF01404;PF01448;PF01462;PF01485;PF01585;PF01753;PF02037;PF02148;PF02177;PF02201;PF02210;PF02214;PF02225;PF02709;PF02825;PF02845;PF02893;PF03062;PF03133;PF03165;PF03256;PF03607;PF04055;PF04762;PF04810;PF05773;PF06325;PF07645;PF07653;PF07679;PF07707;PF07719;PF08210;PF10277;PF10409;PF11717;PF12697;PF12796;PF12895;PF12906;PF12924;PF13091;PF13344;PF13414;PF13415;PF13426;PF13499;PF13646;PF13733;PF13765;PF13831;PF13832;PF13855;PF13857;PF13920;PF13964;PF14324
Group	GO:0023052	signaling	1	10.00	1.64e-19	6.29e-18	102|240|648|3527	PF00014;PF00019;PF00023;PF00025;PF00027;PF00028;PF00041;PF00049;PF00057;PF00071;PF00076;PF00090;PF00096;PF00098;PF00102;PF00106;PF00122;PF00130;PF00134;PF00169;PF00179;PF00225;PF00226;PF00240;PF00249;PF00341;PF00388;PF00397;PF00400;PF00435;PF00452;PF00514;PF00581;PF00610;PF00611;PF00612;PF00618;PF00621;PF00622;PF00625;PF00640;PF00643;PF00651;PF00683;PF00684;PF00688;PF00689;PF00690;PF00702;PF00757;PF00778;PF00780;PF00786;PF00969;PF00989;PF01030;PF01064;PF01217;PF01370;PF01391;PF01403;PF01404;PF01417;PF01421;PF01437;PF01462;PF01465;PF01833;PF01843;PF02023;PF02140;PF02145;PF02177;PF02210;PF02214;PF02377;PF02759;PF02825;PF02828;PF02931;PF03165;PF05790;PF07525;PF07645;PF07653;PF07679;PF07707;PF07719;PF08246;PF08447;PF09279;PF10277;PF10409;PF12763;PF12796;PF12874;PF12924;PF13426;PF13499;PF13716;PF13855;PF13857
Group	GO:0010646	regulation of cell communication	1	10.51	6.86e-19	2.31e-17	69|240|336|3527	PF00019;PF00027;PF00028;PF00040;PF00041;PF00049;PF00057;PF00071;PF00093;PF00096;PF00102;PF00122;PF00130;PF00169;PF00179;PF00240;PF00249;PF00341;PF00400;PF00435;PF00452;PF00514;PF00581;PF00594;PF00618;PF00640;PF00651;PF00683;PF00688;PF00689;PF00690;PF00702;PF00757;PF00778;PF00780;PF00786;PF00969;PF01030;PF01064;PF01391;PF01403;PF01417;PF01437;PF01448;PF01485;PF01585;PF01699;PF01833;PF02037;PF02145;PF02210;PF02214;PF02825;PF02931;PF03165;PF04055;PF07525;PF07645;PF07653;PF07679;PF10409;PF12763;PF12796;PF13499;PF13716;PF13855;PF13857;PF13920;PF14324
Group	GO:0019538	protein metabolic process	1	9.13	1.24e-17	4.03e-16	118|240|869|3527	PF00014;PF00019;PF00023;PF00025;PF00027;PF00040;PF00041;PF00045;PF00049;PF00054;PF00057;PF00071;PF00076;PF00082;PF00090;PF00102;PF00122;PF00130;PF00133;PF00134;PF00169;PF00179;PF00225;PF00226;PF00240;PF00249;PF00254;PF00341;PF00397;PF00400;PF00413;PF00415;PF00452;PF00514;PF00581;PF00583;PF00594;PF00611;PF00612;PF00622;PF00640;PF00643;PF00651;PF00684;PF00688;PF00702;PF00757;PF00780;PF00786;PF00789;PF00899;PF00989;PF01030;PF01064;PF01336;PF01391;PF01404;PF01421;PF01448;PF01462;PF01485;PF01546;PF01753;PF02037;PF02148;PF02177;PF02201;PF02210;PF02214;PF02225;PF02709;PF02825;PF02845;PF02893;PF03062;PF03133;PF03147;PF03165;PF03256;PF03607;PF04055;PF04137;PF04810;PF05773;PF06325;PF07645;PF07653;PF07679;PF07687;PF07707;PF07719;PF08246;PF08662;PF09409;PF10277;PF10409;PF11717;PF12697;PF12796;PF12895;PF12906;PF12924;PF13344;PF13414;PF13415;PF13426;PF13499;PF13589;PF13646;PF13733;PF13765;PF13831;PF13832;PF13855;PF13857;PF13920;PF13964;PF14324
Group	GO:0007163	establishment or maintenance of cell polarity	1	11.58	2.23e-17	6.71e-16	33|240|88|3527	PF00023;PF00028;PF00041;PF00052;PF00053;PF00054;PF00057;PF00071;PF00130;PF00169;PF00225;PF00400;PF00435;PF00610;PF00612;PF00621;PF00625;PF00651;PF00778;PF00786;PF01369;PF01404;PF01843;PF02181;PF02210;PF02828;PF06367;PF06371;PF07653;PF07679;PF12348;PF13499;PF13855
Group	GO:0042221	response to chemical stimulus	1	9.19	8.94e-17	2.60e-15	94|240|615|3527	PF00014;PF00019;PF00023;PF00027;PF00040;PF00041;PF00045;PF00049;PF00052;PF00053;PF00054;PF00055;PF00057;PF00071;PF00076;PF00090;PF00093;PF00096;PF00098;PF00102;PF00122;PF00130;PF00134;PF00153;PF00169;PF00179;PF00225;PF00226;PF00240;PF00249;PF00341;PF00388;PF00397;PF00400;PF00413;PF00435;PF00452;PF00514;PF00583;PF00594;PF00612;PF00621;PF00622;PF00625;PF00640;PF00651;PF00688;PF00689;PF00690;PF00702;PF00757;PF00778;PF00780;PF00786;PF00969;PF00989;PF01030;PF01064;PF01179;PF01370;PF01391;PF01403;PF01404;PF01437;PF01462;PF01833;PF01909;PF02145;PF02148;PF02177;PF02210;PF02931;PF03165;PF06920;PF07525;PF07645;PF07653;PF07679;PF07719;PF08246;PF08416;PF08447;PF09279;PF10409;PF10421;PF12348;PF12796;PF12924;PF13426;PF13499;PF13716;PF13765;PF13855;PF14429
Group	GO:0050793	regulation of developmental process	1	9.53	1.24e-16	3.47e-15	73|240|405|3527	PF00019;PF00025;PF00028;PF00041;PF00049;PF00057;PF00071;PF00076;PF00090;PF00093;PF00096;PF00098;PF00102;PF00125;PF00130;PF00134;PF00169;PF00179;PF00225;PF00241;PF00249;PF00254;PF00341;PF00400;PF00435;PF00452;PF00514;PF00594;PF00610;PF00611;PF00612;PF00618;PF00621;PF00622;PF00640;PF00643;PF00651;PF00688;PF00778;PF00780;PF00786;PF01064;PF01391;PF01403;PF01404;PF01417;PF01437;PF01462;PF01753;PF01833;PF01843;PF02037;PF02177;PF02181;PF02210;PF02377;PF02931;PF03165;PF06367;PF06371;PF07525;PF07645;PF07679;PF08246;PF10409;PF12763;PF12796;PF12906;PF12924;PF12947;PF13414;PF13716;PF13855
Group	GO:0031323	regulation of cellular metabolic process	1	8.39	3.19e-15	8.40e-14	113|240|867|3527	PF00014;PF00019;PF00023;PF00027;PF00028;PF00041;PF00049;PF00054;PF00057;PF00071;PF00076;PF00096;PF00098;PF00102;PF00125;PF00130;PF00134;PF00169;PF00179;PF00225;PF00226;PF00240;PF00249;PF00254;PF00341;PF00389;PF00397;PF00400;PF00415;PF00435;PF00452;PF00514;PF00581;PF00594;PF00610;PF00611;PF00612;PF00618;PF00621;PF00625;PF00640;PF00643;PF00651;PF00688;PF00757;PF00778;PF00780;PF00786;PF00789;PF00899;PF00989;PF01030;PF01064;PF01336;PF01352;PF01391;PF01403;PF01404;PF01437;PF01448;PF01477;PF01585;PF01753;PF01833;PF02023;PF02037;PF02145;PF02148;PF02177;PF02201;PF02210;PF02377;PF02826;PF02845;PF02931;PF03165;PF04055;PF04762;PF05773;PF06920;PF07258;PF07500;PF07525;PF07528;PF07645;PF07653;PF07679;PF07719;PF08210;PF08447;PF08662;PF09816;PF11717;PF12171;PF12697;PF12756;PF12763;PF12796;PF12895;PF12924;PF13414;PF13415;PF13499;PF13716;PF13765;PF13831;PF13832;PF13854;PF13855;PF13857;PF13920;PF14324;PF14429
Group	GO:0051234	establishment of localization	1	8.45	3.57e-15	9.11e-14	106|240|785|3527	PF00014;PF00019;PF00023;PF00025;PF00027;PF00040;PF00041;PF00049;PF00053;PF00057;PF00071;PF00076;PF00102;PF00106;PF00122;PF00130;PF00153;PF00169;PF00179;PF00225;PF00226;PF00241;PF00249;PF00254;PF00341;PF00350;PF00388;PF00397;PF00400;PF00435;PF00452;PF00514;PF00581;PF00610;PF00611;PF00612;PF00618;PF00622;PF00625;PF00640;PF00651;PF00683;PF00688;PF00689;PF00690;PF00702;PF00780;PF00989;PF01064;PF01217;PF01369;PF01391;PF01417;PF01448;PF01465;PF01477;PF01496;PF01553;PF01699;PF01833;PF01843;PF02064;PF02145;PF02177;PF02210;PF02214;PF02225;PF02828;PF02893;PF02931;PF03810;PF04144;PF04695;PF04810;PF06472;PF07258;PF07645;PF07653;PF07679;PF07707;PF07719;PF07728;PF08246;PF08389;PF08393;PF08447;PF09279;PF09324;PF10277;PF12763;PF12774;PF12775;PF12780;PF12783;PF12796;PF12924;PF12947;PF13246;PF13347;PF13385;PF13414;PF13415;PF13418;PF13426;PF13499;PF13855
Group	GO:0000003	reproduction	1	8.94	4.74e-15	1.11e-13	71|240|412|3527	PF00014;PF00019;PF00028;PF00041;PF00045;PF00049;PF00053;PF00055;PF00071;PF00076;PF00096;PF00098;PF00106;PF00122;PF00125;PF00130;PF00134;PF00169;PF00179;PF00188;PF00225;PF00226;PF00240;PF00249;PF00350;PF00388;PF00400;PF00413;PF00435;PF00452;PF00514;PF00612;PF00618;PF00621;PF00622;PF00651;PF00684;PF00688;PF00702;PF00757;PF00780;PF00786;PF00989;PF01030;PF01064;PF01335;PF01421;PF01462;PF01465;PF01553;PF01753;PF02037;PF02177;PF02181;PF02931;PF03062;PF03165;PF06325;PF07525;PF07653;PF07679;PF09279;PF09335;PF12478;PF12796;PF12924;PF13091;PF13589;PF13855;PF13857;PF13920
Group	GO:0051716	cellular response to stimulus	1	8.11	2.36e-14	5.24e-13	110|240|853|3527	PF00014;PF00019;PF00023;PF00025;PF00027;PF00040;PF00041;PF00049;PF00057;PF00071;PF00076;PF00082;PF00090;PF00093;PF00096;PF00098;PF00102;PF00106;PF00122;PF00125;PF00130;PF00134;PF00169;PF00179;PF00225;PF00226;PF00240;PF00249;PF00341;PF00388;PF00397;PF00400;PF00435;PF00452;PF00514;PF00581;PF00583;PF00594;PF00610;PF00611;PF00612;PF00618;PF00621;PF00622;PF00625;PF00640;PF00643;PF00651;PF00683;PF00684;PF00688;PF00689;PF00690;PF00702;PF00757;PF00778;PF00780;PF00786;PF00899;PF00969;PF00989;PF01030;PF01064;PF01179;PF01336;PF01370;PF01391;PF01403;PF01404;PF01417;PF01437;PF01462;PF01833;PF01843;PF01909;PF02037;PF02140;PF02145;PF02177;PF02377;PF02759;PF02825;PF02931;PF03165;PF05773;PF05790;PF07525;PF07645;PF07653;PF07679;PF07707;PF07719;PF08246;PF08447;PF09279;PF10277;PF10409;PF10421;PF11717;PF12763;PF12796;PF12874;PF12924;PF13426;PF13499;PF13589;PF13716;PF13855;PF13857;PF14324
Group	GO:0080090	regulation of primary metabolic process	1	8.00	4.79e-14	1.01e-12	110|240|861|3527	PF00014;PF00019;PF00023;PF00027;PF00041;PF00049;PF00054;PF00057;PF00071;PF00076;PF00096;PF00098;PF00102;PF00125;PF00130;PF00134;PF00169;PF00179;PF00225;PF00226;PF00240;PF00249;PF00341;PF00389;PF00397;PF00400;PF00415;PF00435;PF00452;PF00514;PF00581;PF00594;PF00610;PF00611;PF00612;PF00618;PF00621;PF00640;PF00643;PF00651;PF00688;PF00757;PF00778;PF00780;PF00786;PF00789;PF00899;PF00989;PF01030;PF01064;PF01335;PF01336;PF01352;PF01391;PF01403;PF01404;PF01437;PF01448;PF01585;PF01753;PF01833;PF02023;PF02037;PF02145;PF02148;PF02177;PF02201;PF02210;PF02377;PF02826;PF02845;PF02931;PF03165;PF04055;PF04762;PF05773;PF06920;PF07258;PF07500;PF07525;PF07528;PF07645;PF07653;PF07679;PF07719;PF08210;PF08447;PF08662;PF09816;PF11717;PF12171;PF12697;PF12756;PF12763;PF12796;PF12895;PF12924;PF13414;PF13415;PF13499;PF13716;PF13765;PF13831;PF13832;PF13854;PF13855;PF13857;PF13920;PF14324;PF14429
Group	GO:0060255	regulation of macromolecule metabolic process	1	7.91	8.79e-14	1.81e-12	110|240|868|3527	PF00014;PF00019;PF00023;PF00027;PF00041;PF00049;PF00054;PF00057;PF00071;PF00076;PF00096;PF00098;PF00102;PF00125;PF00130;PF00134;PF00169;PF00179;PF00225;PF00226;PF00240;PF00249;PF00341;PF00389;PF00397;PF00400;PF00415;PF00435;PF00452;PF00514;PF00581;PF00594;PF00610;PF00621;PF00640;PF00643;PF00651;PF00688;PF00757;PF00778;PF00780;PF00786;PF00789;PF00899;PF00989;PF01030;PF01064;PF01335;PF01336;PF01352;PF01391;PF01403;PF01404;PF01437;PF01448;PF01477;PF01585;PF01753;PF01833;PF02023;PF02037;PF02145;PF02148;PF02177;PF02201;PF02210;PF02377;PF02826;PF02845;PF02931;PF03165;PF04055;PF04762;PF05773;PF06325;PF07258;PF07500;PF07525;PF07528;PF07645;PF07653;PF07679;PF07719;PF08210;PF08246;PF08447;PF08662;PF09816;PF10409;PF11717;PF12171;PF12756;PF12763;PF12796;PF12895;PF12924;PF13091;PF13414;PF13415;PF13499;PF13638;PF13716;PF13765;PF13831;PF13832;PF13854;PF13855;PF13857;PF13920;PF14324
Group	GO:0033036	macromolecule localization	1	7.32	9.61e-11	1.28e-09	57|240|354|3527	PF00019;PF00023;PF00025;PF00041;PF00052;PF00053;PF00054;PF00057;PF00071;PF00076;PF00122;PF00130;PF00169;PF00225;PF00226;PF00240;PF00241;PF00350;PF00397;PF00400;PF00435;PF00514;PF00581;PF00611;PF00625;PF00683;PF00688;PF00778;PF01064;PF01217;PF01391;PF01465;PF01477;PF02064;PF02145;PF02210;PF02828;PF03810;PF04144;PF04695;PF04810;PF06472;PF07645;PF07653;PF07679;PF08389;PF10277;PF10409;PF12348;PF12763;PF12796;PF13246;PF13414;PF13415;PF13418;PF13499;PF13855
Group	GO:0051171	regulation of nitrogen compound metabolic process	1	6.73	3.55e-10	4.22e-09	83|240|647|3527	PF00019;PF00023;PF00027;PF00041;PF00049;PF00071;PF00076;PF00096;PF00098;PF00125;PF00130;PF00134;PF00169;PF00179;PF00225;PF00226;PF00249;PF00341;PF00389;PF00397;PF00400;PF00435;PF00514;PF00610;PF00611;PF00612;PF00618;PF00621;PF00643;PF00651;PF00688;PF00757;PF00780;PF00899;PF00989;PF01030;PF01336;PF01352;PF01391;PF01403;PF01404;PF01437;PF01448;PF01585;PF01753;PF01833;PF02023;PF02037;PF02145;PF02177;PF02201;PF02826;PF03165;PF04762;PF06920;PF07258;PF07500;PF07528;PF07645;PF07653;PF07679;PF07719;PF08210;PF08447;PF09816;PF11717;PF12171;PF12756;PF12796;PF12895;PF12924;PF13414;PF13415;PF13499;PF13716;PF13831;PF13832;PF13854;PF13855;PF13857;PF13920;PF14324;PF14429
Group	GO:0006950	response to stress	1	6.63	4.74e-10	5.25e-09	88|240|709|3527	PF00019;PF00023;PF00027;PF00040;PF00041;PF00045;PF00049;PF00057;PF00071;PF00076;PF00082;PF00093;PF00098;PF00102;PF00122;PF00125;PF00130;PF00134;PF00169;PF00179;PF00225;PF00226;PF00240;PF00249;PF00341;PF00350;PF00400;PF00413;PF00435;PF00452;PF00581;PF00594;PF00618;PF00622;PF00625;PF00640;PF00643;PF00651;PF00684;PF00688;PF00689;PF00690;PF00702;PF00757;PF00780;PF00786;PF00899;PF00969;PF00989;PF01030;PF01179;PF01336;PF01391;PF01404;PF01476;PF01477;PF01833;PF01843;PF01909;PF02037;PF02145;PF02177;PF02210;PF02931;PF04055;PF05773;PF05790;PF06920;PF07534;PF07645;PF07653;PF07679;PF08246;PF08447;PF10277;PF10409;PF10421;PF11717;PF12697;PF12924;PF12947;PF13499;PF13589;PF13716;PF13765;PF13855;PF14324;PF14429
Group	GO:0002376	immune system process	1	6.91	9.19e-10	9.67e-09	53|240|334|3527	PF00019;PF00023;PF00041;PF00057;PF00071;PF00090;PF00096;PF00102;PF00130;PF00153;PF00169;PF00179;PF00240;PF00249;PF00254;PF00341;PF00350;PF00388;PF00452;PF00514;PF00594;PF00612;PF00621;PF00625;PF00643;PF00651;PF00688;PF00780;PF00969;PF01335;PF01391;PF01404;PF01476;PF01909;PF02037;PF02931;PF04055;PF04810;PF05790;PF07534;PF07645;PF07653;PF07679;PF08246;PF09279;PF10409;PF10421;PF12697;PF12796;PF13499;PF13855;PF13857;PF14324
Group	GO:0044260	cellular macromolecule metabolic process	1	5.05	4.20e-07	2.97e-06	134|240|1425|3527	PF00014;PF00019;PF00023;PF00025;PF00027;PF00041;PF00049;PF00054;PF00057;PF00071;PF00076;PF00082;PF00096;PF00098;PF00102;PF00122;PF00125;PF00130;PF00133;PF00134;PF00169;PF00179;PF00225;PF00226;PF00240;PF00249;PF00254;PF00341;PF00383;PF00397;PF00400;PF00415;PF00452;PF00514;PF00581;PF00583;PF00594;PF00611;PF00622;PF00640;PF00643;PF00651;PF00684;PF00688;PF00702;PF00757;PF00773;PF00780;PF00786;PF00789;PF00899;PF00989;PF01030;PF01064;PF01336;PF01370;PF01404;PF01448;PF01462;PF01480;PF01485;PF01585;PF01753;PF01909;PF02023;PF02037;PF02148;PF02177;PF02201;PF02210;PF02214;PF02225;PF02269;PF02709;PF02825;PF02845;PF02878;PF02893;PF03062;PF03133;PF03147;PF03165;PF03256;PF03607;PF03828;PF04055;PF04137;PF04762;PF04810;PF05485;PF05773;PF06325;PF07034;PF07500;PF07528;PF07645;PF07653;PF07679;PF07707;PF07719;PF08075;PF08210;PF08447;PF08662;PF09409;PF10277;PF10409;PF11717;PF12171;PF12697;PF12796;PF12874;PF12895;PF12906;PF12924;PF13091;PF13344;PF13414;PF13415;PF13426;PF13499;PF13589;PF13638;PF13646;PF13691;PF13733;PF13765;PF13831;PF13832;PF13855;PF13857;PF13920;PF13964;PF14324
Group	GO:0009889	regulation of biosynthetic process	1	4.67	7.05e-06	3.69e-05	71|240|646|3527	PF00014;PF00019;PF00023;PF00049;PF00076;PF00096;PF00098;PF00125;PF00130;PF00134;PF00169;PF00179;PF00225;PF00249;PF00341;PF00389;PF00397;PF00400;PF00435;PF00514;PF00621;PF00643;PF00651;PF00688;PF00757;PF00899;PF00989;PF01030;PF01064;PF01336;PF01352;PF01391;PF01448;PF01585;PF01753;PF01833;PF02023;PF02037;PF02177;PF02201;PF02826;PF03165;PF04762;PF05773;PF07258;PF07500;PF07528;PF07645;PF07679;PF07719;PF08210;PF08447;PF08662;PF09816;PF11717;PF12171;PF12756;PF12796;PF12895;PF12924;PF13414;PF13415;PF13499;PF13716;PF13831;PF13832;PF13854;PF13855;PF13857;PF13920;PF14324
Group	GO:0009056	catabolic process	1	4.27	4.07e-05	1.77e-04	60|240|543|3527	PF00019;PF00025;PF00049;PF00071;PF00082;PF00098;PF00122;PF00134;PF00153;PF00179;PF00205;PF00225;PF00226;PF00240;PF00350;PF00383;PF00397;PF00400;PF00452;PF00456;PF00583;PF00612;PF00622;PF00643;PF00688;PF00689;PF00690;PF00702;PF00773;PF00789;PF00899;PF00970;PF01370;PF01391;PF01477;PF01485;PF01546;PF01597;PF01909;PF02148;PF02214;PF02825;PF02845;PF03256;PF03828;PF06472;PF07707;PF07728;PF08210;PF08246;PF08442;PF09409;PF10409;PF12697;PF12895;PF13414;PF13589;PF13638;PF13646;PF13920
Group	GO:0001932	regulation of protein phosphorylation	2	11.42	3.84e-19	1.40e-17	48|240|169|3527	PF00014;PF00019;PF00023;PF00027;PF00041;PF00049;PF00057;PF00071;PF00102;PF00134;PF00169;PF00226;PF00240;PF00341;PF00400;PF00415;PF00452;PF00581;PF00594;PF00610;PF00640;PF00688;PF00757;PF00778;PF00780;PF00786;PF01030;PF01064;PF01391;PF01403;PF01437;PF01585;PF02145;PF02177;PF02210;PF02377;PF02931;PF04055;PF07525;PF07645;PF07653;PF07679;PF12796;PF12924;PF13499;PF13716;PF13855;PF13920
Group	GO:0016477	cell migration	2	11.22	6.61e-19	2.31e-17	50|240|185|3527	PF00019;PF00028;PF00041;PF00045;PF00052;PF00053;PF00054;PF00055;PF00057;PF00071;PF00096;PF00102;PF00130;PF00341;PF00397;PF00413;PF00435;PF00594;PF00611;PF00612;PF00618;PF00621;PF00640;PF00688;PF00757;PF00778;PF01030;PF01064;PF01403;PF01404;PF01437;PF01462;PF01833;PF02148;PF02210;PF02214;PF03607;PF06297;PF06367;PF06371;PF06920;PF07645;PF07653;PF07679;PF08447;PF10409;PF12348;PF13414;PF13855;PF14429
Group	GO:0060541	respiratory system development	2	11.72	1.77e-17	5.51e-16	32|240|82|3527	PF00019;PF00028;PF00041;PF00045;PF00049;PF00057;PF00102;PF00130;PF00240;PF00341;PF00413;PF00435;PF00621;PF00625;PF00640;PF00688;PF01064;PF01391;PF02037;PF02181;PF02828;PF03165;PF06367;PF06371;PF07645;PF07653;PF07679;PF08246;PF08447;PF10409;PF13855;PF13903
Group	GO:0051130	positive regulation of cellular component organization	2	10.64	9.44e-16	2.56e-14	34|240|104|3527	PF00019;PF00025;PF00041;PF00071;PF00241;PF00249;PF00341;PF00397;PF00400;PF00452;PF00514;PF00594;PF00611;PF00621;PF00625;PF00688;PF00786;PF01064;PF01391;PF01403;PF01404;PF01437;PF01462;PF02181;PF02210;PF03165;PF06367;PF06371;PF07653;PF07679;PF07719;PF12796;PF13091;PF13855
Group	GO:0030198	extracellular matrix organization	2	10.96	4.55e-15	1.09e-13	26|240|63|3527	PF00019;PF00023;PF00041;PF00045;PF00052;PF00053;PF00054;PF00055;PF00057;PF00090;PF00093;PF00397;PF00413;PF00640;PF00688;PF01391;PF01421;PF02177;PF02210;PF02709;PF04810;PF07679;PF12924;PF13716;PF13733;PF13855
Group	GO:0007444	imaginal disc development	2	10.67	4.43e-15	1.09e-13	29|240|79|3527	PF00023;PF00028;PF00041;PF00045;PF00076;PF00096;PF00130;PF00397;PF00413;PF00435;PF00612;PF00621;PF00625;PF00651;PF01064;PF01369;PF01448;PF01476;PF01833;PF02037;PF03165;PF07534;PF07645;PF07653;PF07679;PF12796;PF13855;PF13920;PF14324
Group	GO:0035556	intracellular signal transduction	2	9.46	1.68e-14	3.83e-13	44|240|184|3527	PF00025;PF00027;PF00041;PF00049;PF00071;PF00098;PF00122;PF00130;PF00134;PF00169;PF00240;PF00397;PF00400;PF00435;PF00452;PF00581;PF00610;PF00611;PF00612;PF00618;PF00621;PF00625;PF00640;PF00643;PF00651;PF00689;PF00690;PF00702;PF00780;PF00786;PF01843;PF02145;PF02759;PF07525;PF07645;PF07653;PF07679;PF08246;PF10277;PF10409;PF12763;PF13499;PF13716;PF13855
Group	GO:0043549	regulation of kinase activity	2	9.69	2.70e-14	5.82e-13	37|240|135|3527	PF00014;PF00019;PF00023;PF00027;PF00041;PF00049;PF00071;PF00102;PF00134;PF00169;PF00240;PF00341;PF00400;PF00415;PF00581;PF00621;PF00640;PF00688;PF00778;PF00780;PF00786;PF01391;PF01585;PF02145;PF02177;PF02210;PF02931;PF04055;PF07525;PF07645;PF07653;PF07679;PF12796;PF12924;PF13716;PF13855;PF13920
Group	GO:0051640	organelle localization	2	9.75	1.04e-13	2.08e-12	31|240|100|3527	PF00071;PF00130;PF00169;PF00225;PF00350;PF00388;PF00400;PF00435;PF00612;PF00640;PF00651;PF00780;PF00786;PF01403;PF01843;PF02181;PF02893;PF04810;PF07707;PF07719;PF07728;PF08393;PF09279;PF12171;PF12756;PF12774;PF12775;PF12780;PF13414;PF13499;PF13920
Group	GO:0018193	peptidyl-amino acid modification	2	9.05	3.69e-13	7.22e-12	38|240|153|3527	PF00041;PF00054;PF00071;PF00130;PF00169;PF00240;PF00249;PF00254;PF00341;PF00397;PF00400;PF00581;PF00583;PF00594;PF00611;PF00757;PF00899;PF01030;PF01404;PF01462;PF01753;PF02210;PF02709;PF03062;PF03133;PF04810;PF06325;PF07645;PF07679;PF07719;PF11717;PF12796;PF13414;PF13646;PF13733;PF13831;PF13832;PF13855
Group	GO:0051056	regulation of small GTPase mediated signal transduction	2	9.80	5.57e-13	1.07e-11	25|240|69|3527	PF00041;PF00071;PF00130;PF00169;PF00610;PF00611;PF00612;PF00618;PF00621;PF00651;PF00780;PF01369;PF01403;PF01404;PF01437;PF01833;PF02145;PF02214;PF06920;PF07653;PF07679;PF12796;PF13716;PF13855;PF14429
Group	GO:0007552	metamorphosis	2	9.31	3.46e-12	6.34e-11	25|240|74|3527	PF00023;PF00045;PF00076;PF00096;PF00102;PF00130;PF00397;PF00413;PF00435;PF00612;PF00621;PF00651;PF01064;PF01369;PF01448;PF01476;PF01833;PF03165;PF07534;PF07645;PF07679;PF10409;PF12796;PF13855;PF13920
Group	GO:0007411	axon guidance	2	9.23	3.46e-12	6.34e-11	26|240|80|3527	PF00014;PF00041;PF00052;PF00102;PF00225;PF00397;PF00435;PF00625;PF00651;PF00778;PF00780;PF01064;PF01391;PF01403;PF01404;PF01437;PF01462;PF01833;PF02148;PF02177;PF02210;PF03165;PF07645;PF07679;PF12924;PF13855
Group	GO:0002165	instar larval or pupal development	2	9.14	4.79e-12	8.58e-11	26|240|81|3527	PF00023;PF00045;PF00076;PF00096;PF00102;PF00130;PF00397;PF00413;PF00435;PF00514;PF00612;PF00621;PF00651;PF01064;PF01369;PF01448;PF01476;PF01833;PF03165;PF07534;PF07645;PF07679;PF10409;PF12796;PF13855;PF13920
Group	GO:0009886	post-embryonic morphogenesis	2	9.01	6.07e-12	1.07e-10	27|240|88|3527	PF00023;PF00045;PF00076;PF00096;PF00102;PF00130;PF00225;PF00397;PF00413;PF00435;PF00452;PF00612;PF00621;PF00651;PF01064;PF01369;PF01448;PF01476;PF01833;PF03165;PF07534;PF07645;PF07679;PF10409;PF12796;PF13855;PF13920
Group	GO:0051301	cell division	2	8.89	7.17e-12	1.23e-10	28|240|95|3527	PF00019;PF00025;PF00071;PF00076;PF00096;PF00130;PF00134;PF00169;PF00225;PF00241;PF00350;PF00435;PF00452;PF00514;PF00612;PF00621;PF00640;PF00651;PF00688;PF00780;PF00786;PF01064;PF02181;PF03165;PF06367;PF06371;PF07707;PF13964
Group	GO:0032446	protein modification by small protein conjugation	2	8.66	8.67e-12	1.46e-10	31|240|116|3527	PF00023;PF00179;PF00240;PF00397;PF00415;PF00514;PF00622;PF00643;PF00651;PF00899;PF01485;PF02037;PF02148;PF02201;PF02214;PF02225;PF02825;PF02845;PF03256;PF05773;PF07707;PF07719;PF12796;PF12895;PF12906;PF13414;PF13765;PF13857;PF13920;PF13964;PF14324
Group	GO:0060560	developmental growth involved in morphogenesis	2	9.26	1.14e-11	1.87e-10	22|240|60|3527	PF00014;PF00019;PF00041;PF00057;PF00071;PF00130;PF00621;PF00625;PF00688;PF00786;PF01064;PF01391;PF01843;PF02177;PF02828;PF03607;PF07653;PF07679;PF12796;PF12924;PF13855;PF13857
Group	GO:0009968	negative regulation of signal transduction	2	8.30	1.23e-11	1.99e-10	37|240|162|3527	PF00019;PF00028;PF00041;PF00049;PF00057;PF00093;PF00096;PF00102;PF00130;PF00169;PF00249;PF00400;PF00514;PF00581;PF00640;PF00651;PF00683;PF00688;PF00778;PF01391;PF01448;PF01585;PF01833;PF02037;PF02145;PF02210;PF02214;PF03165;PF07525;PF07645;PF07679;PF10409;PF12763;PF12796;PF13499;PF13855;PF14324
Group	GO:0032270	positive regulation of cellular protein metabolic process	2	8.38	1.48e-11	2.35e-10	34|240|140|3527	PF00019;PF00041;PF00049;PF00057;PF00071;PF00076;PF00134;PF00179;PF00240;PF00249;PF00341;PF00400;PF00594;PF00640;PF00688;PF00757;PF00778;PF00780;PF00786;PF01030;PF01064;PF01391;PF02210;PF02845;PF02931;PF07645;PF07653;PF07679;PF07719;PF12763;PF13414;PF13499;PF13855;PF14324
Group	GO:0042060	wound healing	2	8.81	1.67e-11	2.60e-10	26|240|85|3527	PF00027;PF00041;PF00071;PF00093;PF00122;PF00130;PF00169;PF00225;PF00341;PF00435;PF00594;PF00618;PF00622;PF00643;PF00689;PF00690;PF00702;PF00757;PF00786;PF01030;PF06920;PF07653;PF07679;PF13716;PF13765;PF14429
Group	GO:0034330	cell junction organization	2	9.03	1.84e-11	2.77e-10	23|240|67|3527	PF00019;PF00028;PF00041;PF00052;PF00053;PF00055;PF00071;PF00102;PF00130;PF00169;PF00435;PF00514;PF00625;PF00640;PF00688;PF00786;PF01391;PF02210;PF02828;PF07645;PF07653;PF07679;PF13903
Group	GO:0006461	protein complex assembly	2	8.13	1.84e-11	2.77e-10	39|240|180|3527	PF00019;PF00025;PF00041;PF00093;PF00125;PF00130;PF00134;PF00169;PF00179;PF00225;PF00350;PF00400;PF00452;PF00611;PF00622;PF00625;PF00643;PF00688;PF00757;PF00778;PF00969;PF01030;PF01064;PF01391;PF02148;PF02181;PF02214;PF02893;PF03165;PF04695;PF06309;PF06367;PF06371;PF07645;PF07679;PF07719;PF12763;PF12947;PF13765
Group	GO:0031329	regulation of cellular catabolic process	2	8.35	3.79e-11	5.61e-10	30|240|115|3527	PF00027;PF00041;PF00071;PF00076;PF00130;PF00169;PF00226;PF00240;PF00400;PF00514;PF00610;PF00611;PF00612;PF00618;PF00621;PF00778;PF00780;PF00789;PF01403;PF01404;PF01437;PF02145;PF02148;PF06920;PF07653;PF12697;PF13414;PF13716;PF13855;PF14429
Group	GO:0007268	synaptic transmission	2	8.08	5.21e-11	7.43e-10	34|240|146|3527	PF00014;PF00025;PF00041;PF00071;PF00122;PF00130;PF00169;PF00225;PF00435;PF00621;PF00622;PF00640;PF00651;PF00690;PF00786;PF01064;PF01217;PF01404;PF01417;PF01462;PF02177;PF02210;PF02214;PF02828;PF02931;PF03165;PF07653;PF07679;PF07707;PF12763;PF12796;PF12924;PF13426;PF13855
Group	GO:0060341	regulation of cellular localization	2	8.08	5.21e-11	7.43e-10	34|240|146|3527	PF00019;PF00023;PF00027;PF00071;PF00076;PF00098;PF00169;PF00225;PF00514;PF00594;PF00610;PF00612;PF00618;PF00622;PF00688;PF00757;PF00778;PF00969;PF01030;PF01064;PF01391;PF01833;PF01843;PF02214;PF02931;PF04055;PF04144;PF04810;PF12796;PF13091;PF13499;PF13716;PF13765;PF13855
Group	GO:0035239	tube morphogenesis	2	8.27	6.25e-11	8.78e-10	29|240|110|3527	PF00019;PF00045;PF00049;PF00090;PF00096;PF00130;PF00341;PF00400;PF00413;PF00435;PF00514;PF00621;PF00625;PF00651;PF00688;PF00786;PF00989;PF01391;PF01403;PF01437;PF02145;PF03165;PF07653;PF07679;PF07707;PF08246;PF08447;PF13414;PF13855
Group	GO:2000145	regulation of cell motility	2	8.27	7.98e-11	1.10e-09	28|240|104|3527	PF00019;PF00041;PF00045;PF00055;PF00071;PF00090;PF00093;PF00102;PF00130;PF00341;PF00388;PF00413;PF00625;PF00688;PF00757;PF01030;PF01391;PF01403;PF01437;PF01833;PF07645;PF07653;PF07679;PF08246;PF09279;PF10409;PF13716;PF13855
Group	GO:0048569	post-embryonic organ development	2	8.35	9.32e-11	1.27e-09	26|240|91|3527	PF00023;PF00045;PF00076;PF00096;PF00130;PF00225;PF00249;PF00397;PF00413;PF00435;PF00452;PF00612;PF00621;PF00651;PF01064;PF01369;PF01448;PF01476;PF01833;PF03165;PF07534;PF07645;PF07679;PF12796;PF13855;PF13920
Group	GO:0051241	negative regulation of multicellular organismal process	2	8.54	1.41e-10	1.86e-09	22|240|67|3527	PF00019;PF00041;PF00102;PF00122;PF00169;PF00240;PF00341;PF00594;PF00651;PF00688;PF00689;PF00690;PF00702;PF00969;PF01391;PF01699;PF02931;PF07525;PF07645;PF10409;PF12796;PF13857
Group	GO:0010740	positive regulation of intracellular protein kinase cascade	2	8.38	1.86e-10	2.41e-09	23|240|74|3527	PF00019;PF00041;PF00049;PF00122;PF00130;PF00179;PF00240;PF00341;PF00594;PF00688;PF00689;PF00690;PF00702;PF00757;PF00778;PF00780;PF01030;PF01391;PF01485;PF07653;PF07679;PF12763;PF13920
Group	GO:0001763	morphogenesis of a branching structure	2	8.45	1.96e-10	2.50e-09	22|240|68|3527	PF00019;PF00045;PF00049;PF00090;PF00130;PF00341;PF00413;PF00435;PF00625;PF00688;PF00786;PF01064;PF01403;PF01404;PF01437;PF01833;PF07645;PF07653;PF07679;PF08246;PF08447;PF13855
Group	GO:0030097	hemopoiesis	2	7.95	2.68e-10	3.37e-09	28|240|109|3527	PF00019;PF00023;PF00041;PF00071;PF00096;PF00102;PF00130;PF00153;PF00169;PF00249;PF00341;PF00452;PF00514;PF00612;PF00621;PF00643;PF00651;PF00688;PF00780;PF02037;PF04055;PF05790;PF07645;PF07679;PF12796;PF13855;PF13857;PF14324
Group	GO:0010769	regulation of cell morphogenesis involved in differentiation	2	8.44	2.76e-10	3.41e-09	21|240|63|3527	PF00019;PF00041;PF00435;PF00514;PF00621;PF00688;PF00780;PF01403;PF01404;PF01437;PF01462;PF01833;PF02181;PF02210;PF02931;PF03165;PF06367;PF06371;PF07679;PF13414;PF13855
Group	GO:0007600	sensory perception	2	8.00	3.46e-10	4.16e-09	26|240|96|3527	PF00023;PF00027;PF00028;PF00053;PF00055;PF00071;PF00106;PF00122;PF00350;PF00415;PF00612;PF00625;PF00689;PF00690;PF00702;PF01391;PF01477;PF02931;PF03607;PF07653;PF07679;PF07719;PF12796;PF13385;PF13499;PF13857
Group	GO:0021700	developmental maturation	2	8.26	3.71e-10	4.34e-09	22|240|70|3527	PF00014;PF00019;PF00028;PF00041;PF00071;PF00076;PF00130;PF00134;PF00169;PF00435;PF00622;PF00651;PF00688;PF01833;PF01843;PF02177;PF07525;PF07679;PF12796;PF12924;PF13091;PF13855
Group	GO:0010975	regulation of neuron projection development	2	8.34	3.86e-10	4.45e-09	21|240|64|3527	PF00025;PF00041;PF00096;PF00254;PF00435;PF00611;PF00621;PF00780;PF01403;PF01404;PF01437;PF01462;PF01833;PF02181;PF02931;PF06367;PF06371;PF07679;PF10409;PF12796;PF13855
Group	GO:0044057	regulation of system process	2	7.80	3.97e-10	4.52e-09	29|240|118|3527	PF00019;PF00027;PF00041;PF00071;PF00102;PF00122;PF00130;PF00169;PF00254;PF00341;PF00435;PF00514;PF00618;PF00688;PF00689;PF00690;PF00702;PF01391;PF01699;PF01833;PF02210;PF02214;PF02931;PF07653;PF07679;PF12796;PF13426;PF13855;PF13857
Group	GO:0051347	positive regulation of transferase activity	2	8.13	4.55e-10	5.11e-09	23|240|77|3527	PF00019;PF00041;PF00049;PF00057;PF00071;PF00134;PF00169;PF00240;PF00341;PF00400;PF00621;PF00640;PF00688;PF00778;PF00780;PF00786;PF01391;PF02210;PF02931;PF07645;PF07653;PF07679;PF13855
Group	GO:0048737	imaginal disc-derived appendage development	2	8.33	5.33e-10	5.83e-09	20|240|59|3527	PF00023;PF00076;PF00096;PF00130;PF00397;PF00435;PF00612;PF00621;PF00651;PF01064;PF01369;PF01448;PF01476;PF01833;PF03165;PF07534;PF07645;PF12796;PF13855;PF13920
Group	GO:0007610	behavior	2	7.51	6.28e-10	6.77e-09	33|240|151|3527	PF00014;PF00027;PF00028;PF00057;PF00071;PF00076;PF00096;PF00122;PF00130;PF00397;PF00435;PF00612;PF00625;PF00640;PF00651;PF00689;PF00690;PF00702;PF00970;PF00989;PF01369;PF01421;PF01465;PF01699;PF02177;PF02210;PF02214;PF02931;PF07653;PF12796;PF12924;PF13716;PF13855
Group	GO:0007018	microtubule-based movement	2	8.23	7.51e-10	8.01e-09	20|240|60|3527	PF00014;PF00071;PF00169;PF00225;PF00400;PF00435;PF00612;PF00989;PF01217;PF02177;PF03133;PF07719;PF07728;PF08393;PF08447;PF12774;PF12775;PF12780;PF12924;PF13414
Group	GO:0006508	proteolysis	2	7.26	1.13e-09	1.17e-08	36|240|179|3527	PF00040;PF00045;PF00057;PF00076;PF00082;PF00090;PF00134;PF00179;PF00226;PF00240;PF00397;PF00400;PF00413;PF00452;PF00594;PF00612;PF00622;PF00643;PF00789;PF01421;PF01485;PF01546;PF02148;PF02214;PF02225;PF02825;PF02845;PF03256;PF07687;PF07707;PF08246;PF12895;PF13414;PF13589;PF13646;PF13920
Group	GO:0030900	forebrain development	2	7.81	1.39e-09	1.43e-08	23|240|81|3527	PF00014;PF00019;PF00041;PF00057;PF00096;PF00249;PF00640;PF00688;PF00757;PF01030;PF01064;PF01404;PF01462;PF02177;PF02210;PF03165;PF03607;PF07645;PF07679;PF12924;PF13414;PF13716;PF13855
Group	GO:0051235	maintenance of location	2	8.51	1.93e-09	1.95e-08	15|240|35|3527	PF00023;PF00122;PF00225;PF00241;PF00400;PF00435;PF00683;PF00689;PF00690;PF00702;PF07645;PF12171;PF12348;PF12756;PF12796
Group	GO:0030031	cell projection assembly	2	8.02	2.04e-09	2.05e-08	19|240|57|3527	PF00028;PF00041;PF00071;PF00102;PF00169;PF00225;PF00341;PF00400;PF00581;PF00610;PF00612;PF00621;PF00778;PF01833;PF02377;PF03133;PF03607;PF07719;PF13414
Group	GO:0046903	secretion	2	7.45	2.16e-09	2.14e-08	27|240|111|3527	PF00019;PF00023;PF00025;PF00027;PF00041;PF00071;PF00122;PF00130;PF00169;PF00341;PF00610;PF00612;PF00618;PF00640;PF00683;PF00688;PF00702;PF01217;PF01417;PF01553;PF02210;PF02828;PF02931;PF04144;PF07645;PF07679;PF12763
Group	GO:0044087	regulation of cellular component biogenesis	2	7.42	2.91e-09	2.85e-08	26|240|105|3527	PF00025;PF00041;PF00071;PF00130;PF00241;PF00249;PF00341;PF00400;PF00452;PF00611;PF00612;PF00621;PF00622;PF00625;PF00786;PF01064;PF01404;PF01462;PF02181;PF02210;PF03165;PF06367;PF06371;PF07653;PF10409;PF12796
Group	GO:0006468	protein phosphorylation	2	7.20	3.24e-09	3.13e-08	30|240|136|3527	PF00014;PF00019;PF00027;PF00041;PF00049;PF00130;PF00134;PF00169;PF00225;PF00240;PF00341;PF00611;PF00640;PF00688;PF00757;PF00780;PF00786;PF00989;PF01030;PF01064;PF01404;PF02177;PF03165;PF03607;PF07645;PF07653;PF07679;PF12924;PF13426;PF13855
Group	GO:0010562	positive regulation of phosphorus metabolic process	2	7.39	3.86e-09	3.69e-08	25|240|99|3527	PF00019;PF00041;PF00049;PF00054;PF00057;PF00071;PF00134;PF00240;PF00341;PF00594;PF00640;PF00688;PF00778;PF00780;PF00786;PF01064;PF01391;PF01403;PF02210;PF02931;PF07645;PF07653;PF07679;PF12763;PF13855
Group	GO:0001654	eye development	2	7.27	4.07e-09	3.85e-08	27|240|114|3527	PF00019;PF00028;PF00041;PF00053;PF00071;PF00096;PF00102;PF00130;PF00400;PF00415;PF00452;PF00514;PF00612;PF00618;PF00651;PF00688;PF01064;PF01404;PF01843;PF02037;PF02210;PF03607;PF07679;PF10409;PF13716;PF13920;PF14324
Group	GO:0007169	transmembrane receptor protein tyrosine kinase signaling pathway	2	7.43	5.07e-09	4.70e-08	23|240|86|3527	PF00019;PF00041;PF00049;PF00071;PF00130;PF00169;PF00341;PF00388;PF00618;PF00621;PF00640;PF00688;PF00757;PF01030;PF01404;PF02145;PF07525;PF07645;PF07653;PF07679;PF09279;PF10409;PF13855
Group	GO:1900542	regulation of purine nucleotide metabolic process	2	7.43	5.07e-09	4.70e-08	23|240|86|3527	PF00027;PF00041;PF00071;PF00130;PF00169;PF00226;PF00514;PF00610;PF00611;PF00612;PF00618;PF00621;PF00780;PF01403;PF01404;PF01437;PF02145;PF06920;PF07653;PF13499;PF13716;PF13855;PF14429
Group	GO:0016049	cell growth	2	7.80	5.55e-09	5.08e-08	18|240|54|3527	PF00014;PF00041;PF00071;PF00130;PF00621;PF00651;PF00786;PF01064;PF01843;PF02177;PF03607;PF07679;PF07707;PF12796;PF12924;PF13716;PF13855;PF13857
Group	GO:0035107	appendage morphogenesis	2	7.31	6.37e-09	5.77e-08	24|240|94|3527	PF00023;PF00057;PF00076;PF00096;PF00130;PF00397;PF00435;PF00452;PF00612;PF00621;PF00651;PF01064;PF01369;PF01448;PF01476;PF01833;PF03165;PF07534;PF07645;PF07679;PF07719;PF12796;PF13855;PF13920
Group	GO:0007292	female gamete generation	2	7.29	1.30e-08	1.16e-07	21|240|76|3527	PF00028;PF00071;PF00076;PF00106;PF00130;PF00134;PF00225;PF00350;PF00435;PF00514;PF00612;PF00618;PF00622;PF00651;PF01064;PF03165;PF07525;PF07653;PF07679;PF13091;PF13920
Group	GO:0032535	regulation of cellular component size	2	7.25	2.41e-08	2.11e-07	19|240|65|3527	PF00041;PF00071;PF00130;PF00169;PF00241;PF00400;PF00435;PF00621;PF00786;PF01403;PF01437;PF01462;PF02145;PF02181;PF02210;PF07653;PF07679;PF10409;PF13855
Group	GO:0007346	regulation of mitotic cell cycle	2	6.93	2.40e-08	2.11e-07	24|240|100|3527	PF00014;PF00019;PF00076;PF00096;PF00130;PF00134;PF00225;PF00341;PF00397;PF00452;PF00625;PF00640;PF00688;PF01448;PF02037;PF02148;PF02177;PF07653;PF07679;PF12796;PF12895;PF12924;PF13414;PF14324
Group	GO:0034762	regulation of transmembrane transport	2	6.99	3.52e-08	3.06e-07	21|240|80|3527	PF00019;PF00023;PF00225;PF00254;PF00341;PF00397;PF00514;PF00622;PF00625;PF00688;PF00757;PF00778;PF01030;PF01391;PF02210;PF07653;PF12796;PF13499;PF13716;PF13855;PF13903
Group	GO:0008360	regulation of cell shape	2	7.10	4.87e-08	4.18e-07	18|240|61|3527	PF00071;PF00130;PF00169;PF00341;PF00611;PF00612;PF00618;PF00621;PF00780;PF00786;PF01403;PF01437;PF01843;PF02181;PF06367;PF06371;PF07679;PF10409
Group	GO:0016358	dendrite development	2	7.23	5.68e-08	4.79e-07	16|240|49|3527	PF00014;PF00041;PF00053;PF00096;PF00435;PF00640;PF00780;PF00786;PF01064;PF01404;PF02177;PF03607;PF07653;PF07679;PF12796;PF12924
Group	GO:0003002	regionalization	2	6.51	5.67e-08	4.79e-07	28|240|136|3527	PF00019;PF00028;PF00041;PF00057;PF00076;PF00093;PF00096;PF00102;PF00130;PF00225;PF00249;PF00400;PF00514;PF00612;PF00622;PF00651;PF00688;PF00778;PF01064;PF01448;PF02377;PF03165;PF06297;PF07525;PF07679;PF12796;PF13091;PF13857
Group	GO:0048610	cellular process involved in reproduction	2	6.29	5.94e-08	4.95e-07	35|240|197|3527	PF00019;PF00028;PF00041;PF00071;PF00076;PF00098;PF00130;PF00134;PF00179;PF00225;PF00240;PF00350;PF00388;PF00435;PF00452;PF00612;PF00621;PF00622;PF00651;PF00688;PF00786;PF01064;PF01753;PF02931;PF03165;PF06325;PF07525;PF07653;PF07679;PF09279;PF12796;PF13091;PF13589;PF13857;PF13920
Group	GO:0023061	signal release	2	7.01	6.45e-08	5.32e-07	18|240|62|3527	PF00019;PF00023;PF00025;PF00027;PF00071;PF00130;PF00169;PF00610;PF00618;PF00640;PF00683;PF00688;PF01217;PF01417;PF02210;PF02828;PF07645;PF12763
Group	GO:0051248	negative regulation of protein metabolic process	2	6.47	8.40e-08	6.87e-07	26|240|122|3527	PF00019;PF00023;PF00041;PF00076;PF00098;PF00102;PF00134;PF00226;PF00240;PF00400;PF00452;PF00581;PF00688;PF00789;PF01335;PF01391;PF01585;PF02145;PF02148;PF05773;PF07525;PF12796;PF13499;PF13716;PF13765;PF13920
Group	GO:0043408	regulation of MAPK cascade	2	6.70	8.90e-08	7.21e-07	21|240|84|3527	PF00049;PF00071;PF00130;PF00169;PF00341;PF00397;PF00514;PF00581;PF00625;PF00640;PF00757;PF00778;PF00780;PF00786;PF01030;PF01391;PF01404;PF01843;PF07653;PF07679;PF13855
Group	GO:0060627	regulation of vesicle-mediated transport	2	6.96	9.81e-08	7.79e-07	17|240|57|3527	PF00071;PF00169;PF00341;PF00397;PF00400;PF00594;PF00610;PF00611;PF00618;PF01391;PF01833;PF02145;PF02210;PF04144;PF07645;PF13091;PF13920
Group	GO:0000278	mitotic cell cycle	2	6.39	9.76e-08	7.79e-07	27|240|131|3527	PF00014;PF00019;PF00023;PF00130;PF00134;PF00179;PF00225;PF00400;PF00452;PF00581;PF00688;PF00780;PF01336;PF01833;PF02037;PF02148;PF02177;PF07679;PF07728;PF08393;PF12348;PF12774;PF12775;PF12780;PF12895;PF12924;PF14324
Group	GO:0001558	regulation of cell growth	2	6.74	1.17e-07	9.19e-07	19|240|71|3527	PF00019;PF00041;PF00134;PF00179;PF00226;PF00435;PF00640;PF00643;PF00688;PF00757;PF01030;PF01403;PF01437;PF01462;PF02210;PF07679;PF10409;PF12796;PF13855
Group	GO:0032880	regulation of protein localization	2	6.54	1.84e-07	1.43e-06	20|240|80|3527	PF00019;PF00023;PF00071;PF00225;PF00514;PF00622;PF00688;PF00757;PF00778;PF00969;PF01030;PF01391;PF02210;PF04055;PF04144;PF12796;PF13499;PF13716;PF13765;PF13855
Group	GO:0001822	kidney development	2	6.59	1.90e-07	1.46e-06	19|240|73|3527	PF00019;PF00025;PF00041;PF00096;PF00102;PF00225;PF00240;PF00341;PF00400;PF00452;PF00612;PF00651;PF00688;PF01391;PF07679;PF07707;PF08246;PF13716;PF13857
Group	GO:0008544	epidermis development	2	6.51	2.40e-07	1.82e-06	19|240|74|3527	PF00019;PF00023;PF00093;PF00122;PF00249;PF00400;PF00514;PF00612;PF00622;PF00688;PF00689;PF00702;PF00757;PF01030;PF01391;PF01843;PF07679;PF12796;PF13855
Group	GO:0071310	cellular response to organic substance	2	5.84	2.57e-07	1.94e-06	38|240|237|3527	PF00019;PF00041;PF00049;PF00071;PF00076;PF00093;PF00098;PF00102;PF00130;PF00169;PF00179;PF00226;PF00240;PF00249;PF00341;PF00400;PF00452;PF00514;PF00583;PF00622;PF00640;PF00688;PF00757;PF00969;PF01030;PF01064;PF01179;PF01391;PF01909;PF03165;PF07525;PF07653;PF07679;PF07719;PF10409;PF10421;PF13499;PF13855
Group	GO:0030163	protein catabolic process	2	6.19	2.94e-07	2.19e-06	24|240|113|3527	PF00082;PF00134;PF00179;PF00226;PF00240;PF00397;PF00400;PF00452;PF00622;PF00643;PF00789;PF01485;PF02148;PF02214;PF02825;PF02845;PF03256;PF07707;PF09409;PF12895;PF13414;PF13589;PF13646;PF13920
Group	GO:0045597	positive regulation of cell differentiation	2	6.24	3.41e-07	2.47e-06	22|240|98|3527	PF00019;PF00041;PF00090;PF00093;PF00096;PF00098;PF00130;PF00341;PF00400;PF00514;PF00640;PF00688;PF01064;PF01391;PF01403;PF01437;PF03165;PF07525;PF07645;PF07679;PF12796;PF13855
Group	GO:0051240	positive regulation of multicellular organismal process	2	6.24	3.41e-07	2.47e-06	22|240|98|3527	PF00019;PF00027;PF00054;PF00122;PF00130;PF00169;PF00341;PF00594;PF00688;PF00689;PF00690;PF00702;PF01064;PF01391;PF01699;PF02210;PF04055;PF07645;PF07679;PF12796;PF13716;PF13855
Group	GO:0009416	response to light stimulus	2	6.11	3.40e-07	2.47e-06	25|240|122|3527	PF00014;PF00023;PF00057;PF00076;PF00098;PF00122;PF00134;PF00226;PF00249;PF00400;PF00452;PF00689;PF00690;PF00702;PF00989;PF02037;PF02177;PF02931;PF08447;PF12924;PF13426;PF13499;PF13716;PF13855;PF13857
Group	GO:0016337	cell-cell adhesion	2	6.66	3.93e-07	2.83e-06	15|240|49|3527	PF00028;PF00041;PF00054;PF00102;PF00122;PF00169;PF00514;PF00625;PF00688;PF00689;PF00690;PF00702;PF02210;PF07679;PF13855
Group	GO:0030155	regulation of cell adhesion	2	6.26	4.35e-07	3.05e-06	20|240|84|3527	PF00019;PF00041;PF00093;PF00102;PF00130;PF00169;PF00341;PF00612;PF00651;PF00688;PF01064;PF01369;PF01391;PF01404;PF01421;PF07645;PF07653;PF07679;PF10409;PF13716
Group	GO:0007015	actin filament organization	2	6.42	4.90e-07	3.41e-06	17|240|63|3527	PF00028;PF00071;PF00241;PF00400;PF00611;PF00612;PF00625;PF01064;PF01417;PF02181;PF02214;PF06367;PF06371;PF07653;PF10409;PF12796;PF13499
Group	GO:0031110	regulation of microtubule polymerization or depolymerization	2	6.93	5.00e-07	3.45e-06	12|240|32|3527	PF00025;PF00041;PF00254;PF00435;PF00514;PF00621;PF00622;PF00643;PF12348;PF12796;PF13499;PF13765
Group	GO:0051494	negative regulation of cytoskeleton organization	2	6.74	5.69e-07	3.90e-06	13|240|38|3527	PF00041;PF00241;PF00254;PF00400;PF00435;PF00514;PF00621;PF00622;PF00643;PF07653;PF12348;PF12796;PF13765
Group	GO:0050817	coagulation	2	6.33	6.28e-07	4.26e-06	17|240|64|3527	PF00027;PF00041;PF00071;PF00093;PF00122;PF00130;PF00169;PF00225;PF00341;PF00594;PF00618;PF00689;PF00690;PF00702;PF06920;PF07679;PF14429
Group	GO:0080135	regulation of cellular response to stress	2	6.13	6.55e-07	4.38e-06	20|240|86|3527	PF00023;PF00040;PF00041;PF00049;PF00071;PF00169;PF00179;PF00397;PF00452;PF00625;PF00640;PF00778;PF00780;PF00786;PF01404;PF01753;PF01843;PF02037;PF07653;PF13855
Group	GO:0043269	regulation of ion transport	2	6.13	6.55e-07	4.38e-06	20|240|86|3527	PF00122;PF00169;PF00254;PF00341;PF00397;PF00435;PF00452;PF00514;PF00594;PF00622;PF00625;PF00689;PF00690;PF00702;PF02210;PF07653;PF12796;PF13426;PF13499;PF13903
Group	GO:0030705	cytoskeleton-dependent intracellular transport	2	6.52	7.80e-07	5.17e-06	14|240|45|3527	PF00014;PF00071;PF00169;PF00225;PF00400;PF00435;PF00612;PF00989;PF01217;PF02177;PF07719;PF08447;PF12924;PF13414
Group	GO:0051345	positive regulation of hydrolase activity	2	6.00	8.42e-07	5.54e-06	21|240|95|3527	PF00019;PF00025;PF00041;PF00130;PF00169;PF00226;PF00452;PF00514;PF00610;PF00611;PF00612;PF00643;PF00688;PF01404;PF02145;PF06920;PF07679;PF08246;PF13716;PF13920;PF14429
Group	GO:0044092	negative regulation of molecular function	2	5.73	9.92e-07	6.42e-06	27|240|146|3527	PF00028;PF00041;PF00076;PF00102;PF00134;PF00169;PF00254;PF00397;PF00400;PF00452;PF00581;PF00594;PF00625;PF00688;PF01391;PF01585;PF02145;PF02148;PF02210;PF07258;PF07525;PF07653;PF09324;PF12796;PF13499;PF13716;PF13920
Group	GO:0051051	negative regulation of transport	2	6.16	1.28e-06	8.26e-06	16|240|60|3527	PF00019;PF00023;PF00130;PF00397;PF00400;PF00611;PF00622;PF00688;PF01064;PF01391;PF01833;PF04055;PF12796;PF13499;PF13716;PF13765
Group	GO:0050776	regulation of immune response	2	5.66	1.90e-06	1.20e-05	23|240|116|3527	PF00023;PF00041;PF00057;PF00090;PF00102;PF00130;PF00169;PF00179;PF00240;PF00388;PF00611;PF00625;PF00651;PF00969;PF01391;PF01476;PF04055;PF07534;PF07645;PF07679;PF08246;PF09279;PF13855
Group	GO:0001738	morphogenesis of a polarized epithelium	2	6.52	1.98e-06	1.23e-05	11|240|30|3527	PF00028;PF00053;PF00130;PF00514;PF00612;PF00625;PF00651;PF01843;PF02210;PF02828;PF06297
Group	GO:0048638	regulation of developmental growth	2	5.94	1.99e-06	1.23e-05	17|240|69|3527	PF00019;PF00134;PF00179;PF00435;PF00611;PF00612;PF00621;PF00622;PF00688;PF01064;PF01403;PF01437;PF01462;PF02210;PF03165;PF07679;PF13855
Group	GO:0048511	rhythmic process	2	6.07	2.05e-06	1.26e-05	15|240|55|3527	PF00019;PF00027;PF00041;PF00076;PF00098;PF00249;PF00452;PF00583;PF00688;PF00989;PF01421;PF02931;PF07679;PF08447;PF13716
Group	GO:0042176	regulation of protein catabolic process	2	6.25	2.10e-06	1.28e-05	13|240|42|3527	PF00240;PF00397;PF00400;PF00514;PF00778;PF00789;PF01335;PF02037;PF02148;PF07525;PF13414;PF13920;PF14324
Group	GO:0045199	maintenance of epithelial cell apical/basal polarity	2	7.67	2.33e-06	1.39e-05	6|240|8|3527	PF00052;PF00053;PF00054;PF00057;PF02210;PF07679
Group	GO:0072347	response to anesthetic	2	7.67	2.33e-06	1.39e-05	6|240|8|3527	PF00052;PF00053;PF00054;PF00057;PF02210;PF07679
Group	GO:0043244	regulation of protein complex disassembly	2	6.61	2.33e-06	1.39e-05	10|240|25|3527	PF00041;PF00225;PF00241;PF00435;PF00514;PF00621;PF00622;PF00643;PF12348;PF13765
Group	GO:0051050	positive regulation of transport	2	5.70	2.47e-06	1.46e-05	20|240|93|3527	PF00019;PF00040;PF00049;PF00071;PF00076;PF00169;PF00341;PF00397;PF00400;PF00452;PF00594;PF00688;PF00969;PF01391;PF02210;PF04144;PF12796;PF13091;PF13499;PF13855
Group	GO:0012501	programmed cell death	2	5.47	2.57e-06	1.51e-05	26|240|144|3527	PF00014;PF00027;PF00090;PF00102;PF00130;PF00240;PF00452;PF00514;PF00621;PF00651;PF00757;PF00786;PF00989;PF01030;PF01335;PF01404;PF02177;PF07653;PF08246;PF08447;PF10409;PF12874;PF12924;PF13716;PF13855;PF13920
Group	GO:0002684	positive regulation of immune system process	2	5.57	2.60e-06	1.52e-05	23|240|118|3527	PF00023;PF00041;PF00057;PF00090;PF00096;PF00102;PF00130;PF00169;PF00179;PF00240;PF00388;PF00611;PF00625;PF00651;PF00969;PF01391;PF01476;PF04055;PF05790;PF07534;PF07645;PF09279;PF13855
Group	GO:0045786	negative regulation of cell cycle	2	5.98	2.63e-06	1.53e-05	15|240|56|3527	PF00019;PF00023;PF00106;PF00134;PF00350;PF00397;PF00625;PF00640;PF00688;PF01477;PF02148;PF07645;PF07653;PF07679;PF10409
Group	GO:0051216	cartilage development	2	6.14	2.82e-06	1.63e-05	13|240|43|3527	PF00019;PF00052;PF00053;PF00054;PF00057;PF00093;PF00688;PF01064;PF01391;PF02210;PF03165;PF07645;PF07679
Group	GO:0016569	covalent chromatin modification	2	5.52	3.03e-06	1.74e-05	23|240|119|3527	PF00076;PF00130;PF00134;PF00179;PF00225;PF00249;PF00254;PF00397;PF00400;PF00583;PF00622;PF01448;PF01753;PF02148;PF06325;PF07719;PF11717;PF12796;PF13414;PF13415;PF13831;PF13832;PF13857
Group	GO:0030111	regulation of Wnt receptor signaling pathway	2	5.90	3.35e-06	1.89e-05	15|240|57|3527	PF00019;PF00028;PF00041;PF00057;PF00102;PF00400;PF00514;PF00612;PF00688;PF00778;PF01391;PF02825;PF07679;PF12796;PF13857
Group	GO:0001568	blood vessel development	2	5.56	3.42e-06	1.92e-05	21|240|103|3527	PF00019;PF00090;PF00093;PF00102;PF00106;PF00169;PF00341;PF00618;PF00640;PF00688;PF01064;PF01403;PF01404;PF01437;PF01833;PF02037;PF02210;PF07645;PF07679;PF12796;PF13716
Group	GO:0050890	cognition	2	5.81	4.25e-06	2.35e-05	15|240|58|3527	PF00014;PF00057;PF00071;PF00122;PF00397;PF00689;PF00690;PF00702;PF01699;PF02177;PF02210;PF02931;PF07653;PF12924;PF13716
Group	GO:0030001	metal ion transport	2	5.38	4.28e-06	2.35e-05	24|240|130|3527	PF00023;PF00027;PF00041;PF00102;PF00122;PF00153;PF00254;PF00388;PF00622;PF00625;PF00651;PF00689;PF00690;PF00702;PF01699;PF01833;PF02214;PF02225;PF02931;PF07707;PF09279;PF12796;PF13426;PF13499
Group	GO:0048732	gland development	2	5.57	4.90e-06	2.68e-05	18|240|81|3527	PF00041;PF00049;PF00096;PF00102;PF00122;PF00341;PF00514;PF00702;PF00757;PF00989;PF01030;PF01391;PF01403;PF01553;PF02210;PF07679;PF10409;PF13716
Group	GO:0042981	regulation of apoptotic process	2	5.07	5.33e-06	2.90e-05	35|240|236|3527	PF00019;PF00041;PF00049;PF00071;PF00082;PF00090;PF00130;PF00169;PF00240;PF00341;PF00397;PF00452;PF00514;PF00594;PF00621;PF00640;PF00643;PF00688;PF00757;PF01030;PF01064;PF01335;PF01391;PF01404;PF01585;PF02037;PF07653;PF07679;PF08246;PF10277;PF10409;PF12763;PF13716;PF13855;PF13920
Group	GO:0031532	actin cytoskeleton reorganization	2	6.61	5.82e-06	3.14e-05	8|240|17|3527	PF00122;PF00130;PF00612;PF00640;PF00689;PF00690;PF00702;PF00780
Group	GO:0050878	regulation of body fluid levels	2	5.51	5.91e-06	3.17e-05	18|240|82|3527	PF00027;PF00041;PF00093;PF00102;PF00122;PF00130;PF00169;PF00225;PF00341;PF00594;PF00618;PF00689;PF00690;PF00702;PF01553;PF06920;PF07679;PF14429
Group	GO:0010564	regulation of cell cycle process	2	5.29	6.32e-06	3.37e-05	23|240|124|3527	PF00019;PF00071;PF00076;PF00130;PF00134;PF00225;PF00240;PF00341;PF00397;PF00400;PF00452;PF00514;PF00640;PF00688;PF01336;PF01448;PF02037;PF02148;PF07679;PF12796;PF12895;PF13414;PF14324
Group	GO:0072511	divalent inorganic cation transport	2	5.46	9.41e-06	4.83e-05	16|240|69|3527	PF00023;PF00041;PF00102;PF00122;PF00254;PF00388;PF00622;PF00625;PF00689;PF00690;PF00702;PF01699;PF01833;PF02931;PF09279;PF12796
Group	GO:0008038	neuron recognition	2	6.18	9.48e-06	4.84e-05	9|240|23|3527	PF00014;PF00041;PF00435;PF00651;PF01404;PF01437;PF02177;PF07679;PF12924
Group	GO:0036075	replacement ossification	2	6.36	9.87e-06	4.97e-05	8|240|18|3527	PF00019;PF00052;PF00053;PF00054;PF00057;PF00688;PF02210;PF07679
Group	GO:0045765	regulation of angiogenesis	2	5.62	1.09e-05	5.46e-05	13|240|48|3527	PF00041;PF00071;PF00090;PF00093;PF00102;PF00130;PF00169;PF00341;PF00643;PF07645;PF08246;PF12947;PF13716
Group	GO:0032970	regulation of actin filament-based process	2	5.53	1.10e-05	5.46e-05	14|240|55|3527	PF00041;PF00071;PF00130;PF00169;PF00241;PF00400;PF00610;PF00611;PF00621;PF00786;PF01404;PF02181;PF07653;PF12796
Group	GO:0007369	gastrulation	2	5.45	1.37e-05	6.77e-05	14|240|56|3527	PF00019;PF00025;PF00076;PF00102;PF00130;PF00435;PF00583;PF00621;PF00688;PF00778;PF01064;PF03165;PF06297;PF13499
Group	GO:0030003	cellular cation homeostasis	2	5.10	1.37e-05	6.77e-05	21|240|112|3527	PF00014;PF00041;PF00102;PF00122;PF00130;PF00254;PF00388;PF00400;PF00452;PF00622;PF00689;PF00690;PF00702;PF01496;PF01699;PF02177;PF02225;PF02931;PF09279;PF12924;PF13499
Group	GO:0006909	phagocytosis	2	5.52	1.40e-05	6.86e-05	13|240|49|3527	PF00041;PF00053;PF00057;PF00102;PF00106;PF00130;PF00249;PF00400;PF01217;PF01391;PF01448;PF07645;PF07679
Group	GO:0007009	plasma membrane organization	2	5.69	1.51e-05	7.35e-05	11|240|36|3527	PF00054;PF00071;PF00169;PF00435;PF00611;PF00622;PF00643;PF01391;PF02210;PF12796;PF13765
Group	GO:0072507	divalent inorganic cation homeostasis	2	5.25	1.68e-05	8.14e-05	16|240|72|3527	PF00041;PF00102;PF00122;PF00130;PF00254;PF00388;PF00452;PF00622;PF00689;PF00690;PF00702;PF01699;PF02177;PF02931;PF09279;PF12924
Group	GO:0072657	protein localization to membrane	2	5.57	2.02e-05	9.72e-05	11|240|37|3527	PF00053;PF00054;PF00071;PF00169;PF00611;PF00625;PF01391;PF02210;PF07653;PF07679;PF12796
Group	GO:0008213	protein alkylation	2	5.42	2.23e-05	1.04e-04	12|240|44|3527	PF00071;PF00076;PF00134;PF00225;PF00400;PF00622;PF01753;PF06325;PF07719;PF12796;PF13414;PF13857
Group	GO:0001817	regulation of cytokine production	2	5.07	2.42e-05	1.12e-04	17|240|82|3527	PF00019;PF00023;PF00076;PF00130;PF00240;PF00622;PF00651;PF00688;PF00969;PF01391;PF02023;PF02931;PF04055;PF04144;PF12796;PF13765;PF13855
Group	GO:0009798	axis specification	2	5.25	2.82e-05	1.30e-04	13|240|52|3527	PF00057;PF00076;PF00130;PF00400;PF00612;PF00622;PF00651;PF00778;PF01064;PF03165;PF06297;PF07525;PF13091
Group	GO:0019216	regulation of lipid metabolic process	2	5.11	2.83e-05	1.30e-04	15|240|67|3527	PF00019;PF00041;PF00049;PF00071;PF00098;PF00169;PF00341;PF00400;PF00688;PF01391;PF07653;PF07679;PF07719;PF12697;PF13414
Group	GO:0007548	sex differentiation	2	5.05	2.90e-05	1.32e-04	16|240|75|3527	PF00019;PF00041;PF00076;PF00096;PF00098;PF00125;PF00134;PF00400;PF00452;PF00651;PF00688;PF00989;PF01064;PF01421;PF01462;PF07679
Group	GO:0008285	negative regulation of cell proliferation	2	4.91	2.95e-05	1.34e-04	19|240|100|3527	PF00019;PF00102;PF00350;PF00514;PF00625;PF00688;PF00786;PF00969;PF01391;PF01753;PF02145;PF02709;PF03165;PF06297;PF07679;PF07719;PF10409;PF13716;PF13733
Group	GO:0008283	cell proliferation	2	4.76	2.98e-05	1.34e-04	24|240|145|3527	PF00019;PF00027;PF00041;PF00076;PF00096;PF00102;PF00130;PF00134;PF00249;PF00254;PF00341;PF00452;PF00625;PF00640;PF00688;PF01064;PF01404;PF02148;PF03165;PF05485;PF07653;PF07679;PF10409;PF12874
Group	GO:0045596	negative regulation of cell differentiation	2	4.82	3.15e-05	1.41e-04	21|240|118|3527	PF00019;PF00071;PF00098;PF00249;PF00514;PF00688;PF00778;PF00780;PF01064;PF01391;PF01403;PF01404;PF01417;PF02177;PF03165;PF07645;PF07679;PF12796;PF12924;PF13414;PF13716
Group	GO:0044265	cellular macromolecule catabolic process	2	4.56	4.29e-05	1.84e-04	28|240|187|3527	PF00082;PF00098;PF00134;PF00179;PF00226;PF00240;PF00397;PF00400;PF00452;PF00622;PF00643;PF00773;PF00789;PF01485;PF01909;PF02148;PF02214;PF02825;PF02845;PF03256;PF03828;PF07707;PF12895;PF13414;PF13589;PF13638;PF13646;PF13920
Group	GO:0032101	regulation of response to external stimulus	2	4.82	4.32e-05	1.85e-04	18|240|94|3527	PF00019;PF00027;PF00041;PF00130;PF00341;PF00594;PF00625;PF00688;PF01391;PF01403;PF01421;PF01437;PF01462;PF01833;PF02210;PF07653;PF07679;PF13855
Group	GO:0045165	cell fate commitment	2	4.76	4.55e-05	1.94e-04	19|240|103|3527	PF00019;PF00076;PF00096;PF00130;PF00249;PF00435;PF00621;PF00625;PF00651;PF00688;PF00989;PF01064;PF01465;PF02828;PF03165;PF07645;PF07653;PF07679;PF10409
Group	GO:0007283	spermatogenesis	2	4.86	4.85e-05	2.05e-04	16|240|78|3527	PF00041;PF00179;PF00226;PF00240;PF00350;PF00452;PF00612;PF00651;PF00684;PF00780;PF01421;PF01753;PF02037;PF07679;PF12796;PF13091
Group	GO:0032844	regulation of homeostatic process	2	4.91	4.91e-05	2.07e-04	15|240|70|3527	PF00019;PF00041;PF00057;PF00102;PF00179;PF00249;PF00254;PF00388;PF00452;PF00622;PF00688;PF00969;PF09279;PF12796;PF13716
Group	GO:0070482	response to oxygen levels	2	5.00	5.35e-05	2.24e-04	13|240|55|3527	PF00019;PF00023;PF00045;PF00341;PF00413;PF00643;PF00688;PF00989;PF02037;PF02145;PF02931;PF08447;PF13716
Group	GO:0009725	response to hormone stimulus	2	4.50	7.01e-05	2.84e-04	23|240|143|3527	PF00019;PF00041;PF00045;PF00049;PF00102;PF00130;PF00169;PF00249;PF00388;PF00413;PF00452;PF00514;PF00640;PF00688;PF00757;PF01030;PF01064;PF01391;PF07525;PF07653;PF09279;PF10409;PF13855
Group	GO:0007219	Notch signaling pathway	2	5.14	7.11e-05	2.87e-04	10|240|35|3527	PF00023;PF00096;PF00400;PF01370;PF01417;PF01833;PF01843;PF02825;PF07645;PF12796
Group	GO:0055123	digestive system development	2	5.02	7.45e-05	2.99e-04	11|240|42|3527	PF00019;PF00041;PF00049;PF00096;PF00400;PF00621;PF00688;PF00757;PF01030;PF03165;PF07679
Group	GO:0006357	regulation of transcription from RNA polymerase II promoter	2	4.40	7.70e-05	3.07e-04	26|240|173|3527	PF00019;PF00023;PF00049;PF00400;PF00435;PF00514;PF00651;PF00688;PF00989;PF01833;PF02037;PF02177;PF02201;PF03165;PF04762;PF07500;PF07645;PF07679;PF08447;PF12796;PF12924;PF13415;PF13716;PF13854;PF13857;PF13920
Group	GO:0010942	positive regulation of cell death	2	4.49	8.88e-05	3.53e-04	20|240|117|3527	PF00019;PF00041;PF00090;PF00169;PF00240;PF00397;PF00452;PF00514;PF00621;PF00643;PF00688;PF01335;PF01391;PF01404;PF01585;PF07653;PF07679;PF08246;PF10409;PF13716
Group	GO:0050808	synapse organization	2	4.92	9.42e-05	3.71e-04	11|240|43|3527	PF00028;PF00130;PF00625;PF00690;PF02177;PF02210;PF07653;PF07679;PF12796;PF12924;PF13857
Group	GO:0060348	bone development	2	4.92	9.42e-05	3.71e-04	11|240|43|3527	PF00019;PF00052;PF00053;PF00054;PF00057;PF00622;PF00688;PF01391;PF02210;PF07645;PF07679
Group	GO:0051052	regulation of DNA metabolic process	2	4.65	9.69e-05	3.79e-04	15|240|74|3527	PF00019;PF00134;PF00179;PF00225;PF00249;PF00341;PF00651;PF00688;PF01336;PF01391;PF02037;PF07679;PF12171;PF12756;PF12895
Group	GO:0002252	immune effector process	2	4.50	1.13e-04	4.23e-04	17|240|92|3527	PF00041;PF00057;PF00071;PF00090;PF00102;PF00130;PF00969;PF01391;PF01404;PF01909;PF04055;PF07645;PF07679;PF08246;PF10409;PF10421;PF13855
Group	GO:0043069	negative regulation of programmed cell death	2	4.43	1.16e-04	4.30e-04	19|240|110|3527	PF00019;PF00041;PF00049;PF00071;PF00130;PF00169;PF00341;PF00452;PF00594;PF00688;PF00757;PF01030;PF02037;PF07653;PF08246;PF10277;PF12763;PF13855;PF13920
Group	GO:0006836	neurotransmitter transport	2	4.82	1.18e-04	4.36e-04	11|240|44|3527	PF00071;PF00122;PF00130;PF00169;PF00640;PF00690;PF01217;PF01417;PF02210;PF02828;PF12763
Group	GO:0001701	in utero embryonic development	2	4.61	1.63e-04	5.75e-04	12|240|53|3527	PF00169;PF00249;PF00341;PF00640;PF00757;PF00989;PF01030;PF01064;PF01417;PF03165;PF07679;PF08447
Group	GO:2000027	regulation of organ morphogenesis	2	4.54	1.67e-04	5.87e-04	13|240|61|3527	PF00019;PF00400;PF00452;PF00514;PF00610;PF00640;PF00688;PF00778;PF01064;PF02377;PF03165;PF07679;PF12796
Group	GO:0033365	protein localization to organelle	2	4.29	1.68e-04	5.87e-04	19|240|113|3527	PF00019;PF00025;PF00071;PF00226;PF00240;PF00350;PF00397;PF00435;PF00514;PF00688;PF02064;PF02145;PF03810;PF04695;PF07645;PF08389;PF12796;PF13414;PF13499
Group	GO:0034621	cellular macromolecular complex subunit organization	2	4.16	1.68e-04	5.87e-04	25|240|171|3527	PF00019;PF00025;PF00041;PF00076;PF00125;PF00130;PF00134;PF00169;PF00179;PF00225;PF00241;PF00400;PF00583;PF00611;PF00688;PF01064;PF01585;PF02181;PF03165;PF06325;PF06367;PF06371;PF07679;PF07719;PF12874
Group	GO:0016319	mushroom body development	2	5.37	1.76e-04	6.03e-04	6|240|14|3527	PF00041;PF00102;PF00435;PF00621;PF01404;PF07679
Group	GO:0050919	negative chemotaxis	2	5.37	1.76e-04	6.03e-04	6|240|14|3527	PF00341;PF01403;PF01404;PF01462;PF02210;PF13855
Group	GO:0045926	negative regulation of growth	2	4.64	1.82e-04	6.20e-04	11|240|46|3527	PF00019;PF00226;PF00611;PF00622;PF00640;PF00643;PF00688;PF01403;PF01462;PF02210;PF10409
Group	GO:0000279	M phase	2	4.19	1.92e-04	6.52e-04	21|240|133|3527	PF00130;PF00179;PF00225;PF00240;PF00400;PF00621;PF00651;PF00780;PF02148;PF07679;PF07707;PF08393;PF12348;PF12775;PF12780;PF12796;PF12895;PF13091;PF13589;PF13857;PF13964
Group	GO:0051325	interphase	2	4.43	1.93e-04	6.53e-04	14|240|70|3527	PF00014;PF00019;PF00023;PF00096;PF00134;PF00452;PF00581;PF00688;PF01336;PF01833;PF02037;PF02177;PF12924;PF14324
Group	GO:0045321	leukocyte activation	2	4.27	1.94e-04	6.55e-04	18|240|105|3527	PF00041;PF00096;PF00102;PF00130;PF00249;PF00254;PF00452;PF00514;PF00621;PF00625;PF00651;PF00780;PF02931;PF04055;PF05790;PF07653;PF07679;PF13855
Group	GO:0060249	anatomical structure homeostasis	2	4.29	2.20e-04	7.37e-04	16|240|88|3527	PF00041;PF00082;PF00249;PF00397;PF00435;PF00452;PF00514;PF01336;PF01391;PF02023;PF02037;PF02893;PF07679;PF08246;PF12796;PF13857
Group	GO:0048705	skeletal system morphogenesis	2	4.55	2.23e-04	7.41e-04	11|240|47|3527	PF00019;PF00052;PF00053;PF00054;PF00057;PF00688;PF01391;PF02210;PF03165;PF07645;PF07679
Group	GO:0050678	regulation of epithelial cell proliferation	2	4.46	2.36e-04	7.81e-04	12|240|55|3527	PF00019;PF00041;PF00102;PF00130;PF00341;PF00514;PF00688;PF00757;PF01030;PF01064;PF03165;PF07679
Group	GO:0051046	regulation of secretion	2	4.20	2.53e-04	8.33e-04	17|240|98|3527	PF00019;PF00027;PF00040;PF00071;PF00169;PF00610;PF00618;PF00622;PF00688;PF00969;PF01064;PF01833;PF02214;PF02931;PF04055;PF04144;PF13765
Group	GO:0016331	morphogenesis of embryonic epithelium	2	4.33	2.79e-04	9.02e-04	13|240|64|3527	PF00071;PF00096;PF00130;PF00621;PF00625;PF00786;PF01064;PF01843;PF02145;PF02828;PF07653;PF07679;PF12796
Group	GO:0071495	cellular response to endogenous stimulus	2	4.04	3.17e-04	1.01e-03	20|240|128|3527	PF00019;PF00041;PF00049;PF00071;PF00093;PF00102;PF00169;PF00249;PF00452;PF00640;PF00688;PF00757;PF01030;PF01064;PF01179;PF01391;PF07653;PF07679;PF10409;PF13855
Group	GO:0055065	metal ion homeostasis	2	4.09	3.74e-04	1.18e-03	16|240|92|3527	PF00041;PF00102;PF00122;PF00130;PF00254;PF00388;PF00452;PF00622;PF00689;PF00690;PF00702;PF02177;PF02225;PF02931;PF09279;PF12924
Group	GO:0006898	receptor-mediated endocytosis	2	4.59	3.85e-04	1.21e-03	8|240|28|3527	PF00040;PF00057;PF00169;PF00350;PF00397;PF00611;PF07645;PF12947
Group	GO:0007422	peripheral nervous system development	2	4.46	3.97e-04	1.25e-03	9|240|35|3527	PF00019;PF00041;PF00169;PF00621;PF00757;PF01030;PF01421;PF07679;PF13716
Group	GO:0007178	transmembrane receptor protein serine/threonine kinase signaling pathway	2	4.31	4.57e-04	1.40e-03	10|240|43|3527	PF00019;PF00106;PF00341;PF00397;PF00683;PF00688;PF01064;PF03165;PF07645;PF12874
Group	GO:0090092	regulation of transmembrane receptor protein serine/threonine kinase signaling pathway	2	4.31	4.57e-04	1.40e-03	10|240|43|3527	PF00019;PF00090;PF00093;PF00096;PF00683;PF00688;PF01064;PF03165;PF07645;PF12796
Group	GO:1901214	regulation of neuron death	2	4.22	4.79e-04	1.45e-03	11|240|51|3527	PF00041;PF00071;PF00082;PF00169;PF00452;PF01404;PF07653;PF07679;PF12763;PF13716;PF13855
Group	GO:0030855	epithelial cell differentiation	2	4.01	6.03e-04	1.78e-03	13|240|69|3527	PF00019;PF00041;PF00049;PF00102;PF00130;PF00514;PF00612;PF00640;PF00688;PF01064;PF03165;PF07645;PF07679
Group	GO:0042391	regulation of membrane potential	2	3.95	6.25e-04	1.78e-03	14|240|78|3527	PF00041;PF00169;PF00452;PF00612;PF00625;PF01421;PF02023;PF02210;PF02214;PF02931;PF07653;PF07679;PF12796;PF13716
Group	GO:0045927	positive regulation of growth	2	4.03	6.51e-04	1.84e-03	12|240|61|3527	PF00125;PF00133;PF00169;PF00612;PF00621;PF00757;PF00989;PF01030;PF01064;PF03165;PF12796;PF13716
Group	GO:0007519	skeletal muscle tissue development	2	4.03	6.51e-04	1.84e-03	12|240|61|3527	PF00041;PF00049;PF00622;PF00625;PF01369;PF02177;PF06920;PF07679;PF12796;PF12924;PF13414;PF13857
Group	GO:0043122	regulation of I-kappaB kinase/NF-kappaB cascade	2	4.13	6.74e-04	1.90e-03	10|240|45|3527	PF00122;PF00179;PF00240;PF00689;PF00690;PF00702;PF01391;PF01485;PF12796;PF13920
Group	GO:0016055	Wnt receptor signaling pathway	2	4.15	7.65e-04	2.14e-03	9|240|38|3527	PF00049;PF00057;PF00435;PF00514;PF00610;PF00778;PF02377;PF07707;PF13499
Group	GO:0040017	positive regulation of locomotion	2	3.99	8.02e-04	2.23e-03	11|240|54|3527	PF00019;PF00053;PF00055;PF00090;PF00093;PF00130;PF00169;PF00341;PF00688;PF07679;PF08246
Group	GO:0034220	ion transmembrane transport	2	3.83	1.02e-03	2.80e-03	12|240|64|3527	PF00023;PF00027;PF00122;PF00153;PF00452;PF00622;PF00690;PF00702;PF01699;PF02214;PF12796;PF13426
Group	GO:0006605	protein targeting	2	3.63	1.04e-03	2.81e-03	18|240|120|3527	PF00019;PF00071;PF00226;PF00397;PF00435;PF00514;PF00625;PF00688;PF02064;PF02145;PF03810;PF04695;PF07645;PF08389;PF12796;PF13414;PF13499;PF13855
Group	GO:0006955	immune response	2	3.59	1.04e-03	2.81e-03	20|240|140|3527	PF00023;PF00041;PF00057;PF00071;PF00090;PF00130;PF00240;PF00350;PF00651;PF00969;PF01391;PF01404;PF07645;PF07679;PF08246;PF10409;PF12697;PF12796;PF13499;PF13855
Group	GO:0048562	embryonic organ morphogenesis	2	3.89	1.15e-03	2.95e-03	10|240|48|3527	PF00028;PF00052;PF00054;PF00122;PF00689;PF00690;PF00702;PF02210;PF03165;PF07679
Group	GO:0032259	methylation	2	3.68	1.19e-03	2.95e-03	14|240|83|3527	PF00071;PF00076;PF00134;PF00225;PF00400;PF00622;PF01585;PF01753;PF06325;PF07719;PF12796;PF13091;PF13414;PF13857
Group	GO:0048608	reproductive structure development	2	3.59	1.15e-03	2.95e-03	18|240|121|3527	PF00019;PF00041;PF00049;PF00071;PF00076;PF00098;PF00125;PF00134;PF00225;PF00249;PF00400;PF00452;PF00618;PF00651;PF00688;PF01421;PF07679;PF13855
Group	GO:0045892	negative regulation of transcription, DNA-dependent	2	3.53	1.26e-03	3.12e-03	19|240|132|3527	PF00096;PF00125;PF00179;PF00225;PF00389;PF00400;PF00514;PF00651;PF00688;PF01448;PF01585;PF02201;PF02826;PF07679;PF12796;PF13414;PF13415;PF13854;PF13920
Group	GO:0061326	renal tubule development	2	4.00	1.28e-03	3.15e-03	8|240|33|3527	PF00400;PF00621;PF00651;PF01064;PF07679;PF07707;PF12796;PF13414
Group	GO:0008015	blood circulation	2	3.78	1.29e-03	3.16e-03	11|240|57|3527	PF00041;PF00102;PF00122;PF00341;PF00689;PF00690;PF01391;PF02210;PF07679;PF12796;PF13499
Group	GO:0000226	microtubule cytoskeleton organization	2	3.63	1.34e-03	3.28e-03	14|240|84|3527	PF00130;PF00225;PF00400;PF00435;PF00514;PF00621;PF00778;PF02377;PF03133;PF03607;PF07679;PF12348;PF13414;PF13499
Group	GO:0043583	ear development	2	3.73	1.60e-03	3.91e-03	10|240|50|3527	PF00028;PF00049;PF00122;PF00400;PF00689;PF00690;PF00702;PF07645;PF07679;PF13385
Group	GO:0009799	specification of symmetry	2	3.66	1.88e-03	4.47e-03	10|240|51|3527	PF00019;PF00096;PF00225;PF00400;PF00688;PF01064;PF07645;PF07719;PF12796;PF13414
Group	GO:0060173	limb development	2	3.70	1.96e-03	4.62e-03	9|240|43|3527	PF00019;PF00057;PF00096;PF00452;PF00688;PF01448;PF03165;PF07679;PF07719
Group	GO:0015672	monovalent inorganic cation transport	2	3.58	1.99e-03	4.62e-03	11|240|60|3527	PF00027;PF00153;PF00651;PF00690;PF00702;PF01496;PF01699;PF02214;PF07707;PF13426;PF13499
Group	GO:0045893	positive regulation of transcription, DNA-dependent	2	3.31	2.09e-03	4.79e-03	20|240|148|3527	PF00019;PF00023;PF00400;PF00435;PF00514;PF00688;PF00757;PF00989;PF01030;PF01833;PF02037;PF02177;PF03165;PF07645;PF08210;PF08447;PF09816;PF12796;PF12924;PF13716
Group	GO:0010608	posttranscriptional regulation of gene expression	2	3.34	2.25e-03	5.07e-03	17|240|118|3527	PF00014;PF00019;PF00076;PF00098;PF00240;PF00643;PF00757;PF01030;PF02148;PF02177;PF05773;PF08246;PF08662;PF10409;PF12924;PF13499;PF13638
Group	GO:0070848	response to growth factor stimulus	2	3.69	2.33e-03	5.22e-03	8|240|36|3527	PF00071;PF00130;PF00169;PF00341;PF00514;PF00621;PF01064;PF07679
Group	GO:0007498	mesoderm development	2	3.69	2.33e-03	5.22e-03	8|240|36|3527	PF00019;PF00435;PF00621;PF00688;PF01064;PF03165;PF13426;PF13499
Group	GO:0032409	regulation of transporter activity	2	3.62	2.32e-03	5.22e-03	9|240|44|3527	PF00254;PF00397;PF00622;PF00625;PF02210;PF07653;PF12796;PF13499;PF13903
Group	GO:0048678	response to axon injury	2	4.09	2.39e-03	5.26e-03	5|240|15|3527	PF00041;PF00452;PF07645;PF07679;PF13855
Group	GO:0050865	regulation of cell activation	2	3.39	2.51e-03	5.51e-03	13|240|80|3527	PF00019;PF00041;PF00096;PF00102;PF00130;PF00341;PF00594;PF00611;PF00651;PF00688;PF00969;PF05790;PF07653
Group	GO:0017038	protein import	2	3.39	2.99e-03	6.37e-03	11|240|63|3527	PF00019;PF00226;PF00400;PF00514;PF00688;PF02064;PF02145;PF03810;PF04695;PF07645;PF12796
Group	GO:0040029	regulation of gene expression, epigenetic	2	3.29	3.14e-03	6.60e-03	13|240|82|3527	PF00096;PF00098;PF00125;PF00179;PF00225;PF00400;PF06325;PF08210;PF12796;PF13091;PF13414;PF13638;PF13857
Group	GO:0051090	regulation of sequence-specific DNA binding transcription factor activity	2	3.33	3.40e-03	6.96e-03	11|240|64|3527	PF00023;PF00130;PF00169;PF00341;PF00397;PF00621;PF00899;PF07258;PF12796;PF13499;PF13855
Group	GO:0016311	dephosphorylation	2	3.38	3.73e-03	7.59e-03	9|240|47|3527	PF00041;PF00102;PF00581;PF00702;PF02893;PF07679;PF10409;PF13344;PF13499
Group	GO:0009117	nucleotide metabolic process	2	2.98	4.24e-03	8.59e-03	23|240|190|3527	PF00019;PF00025;PF00071;PF00122;PF00225;PF00350;PF00400;PF00456;PF00583;PF00586;PF00612;PF00625;PF00688;PF00689;PF00690;PF00702;PF01370;PF01909;PF02769;PF02878;PF07728;PF10421;PF13589
Group	GO:0060485	mesenchyme development	2	3.25	4.42e-03	8.86e-03	10|240|57|3527	PF00019;PF00096;PF00688;PF00757;PF01030;PF01064;PF01403;PF01833;PF07645;PF07679
Group	GO:0043543	protein acylation	2	3.18	5.04e-03	9.68e-03	10|240|58|3527	PF00025;PF00240;PF00249;PF00400;PF00583;PF03062;PF11717;PF12796;PF13831;PF13832
Group	GO:0009991	response to extracellular stimulus	2	3.00	5.11e-03	9.80e-03	16|240|117|3527	PF00019;PF00027;PF00071;PF00082;PF00096;PF00400;PF00594;PF00618;PF00622;PF00688;PF00899;PF01179;PF05773;PF08246;PF10409;PF13765
Group	GO:0007601	visual perception	3	9.33	2.85e-10	3.48e-09	14|240|27|3527	PF00027;PF00053;PF00055;PF00106;PF00350;PF00415;PF00612;PF00625;PF02931;PF03607;PF07719;PF13385;PF13499;PF13857
Group	GO:0043551	regulation of phosphatidylinositol 3-kinase activity	3	7.87	2.03e-07	1.55e-06	9|240|16|3527	PF00019;PF00041;PF00049;PF00071;PF00169;PF00341;PF00688;PF07653;PF07679
Group	GO:0050920	regulation of chemotaxis	3	7.57	4.06e-07	2.89e-06	9|240|17|3527	PF00019;PF00341;PF00625;PF00688;PF01403;PF01437;PF01833;PF02210;PF07653
Group	GO:0051897	positive regulation of protein kinase B signaling cascade	3	7.49	8.61e-07	5.62e-06	8|240|14|3527	PF00019;PF00049;PF00594;PF00688;PF00757;PF01030;PF07653;PF12763
Group	GO:0045834	positive regulation of lipid metabolic process	3	6.68	1.33e-06	8.51e-06	11|240|29|3527	PF00019;PF00041;PF00049;PF00071;PF00169;PF00341;PF00688;PF01391;PF07653;PF07679;PF12697
Group	GO:0031345	negative regulation of cell projection organization	3	7.04	1.37e-06	8.64e-06	9|240|19|3527	PF00041;PF00096;PF00254;PF00780;PF01403;PF01404;PF01462;PF02210;PF13855
Group	GO:0002028	regulation of sodium ion transport	3	6.88	3.27e-06	1.86e-05	8|240|16|3527	PF00122;PF00169;PF00397;PF00435;PF00689;PF00690;PF00702;PF13499
Group	GO:0051017	actin filament bundle assembly	3	6.43	3.56e-06	1.98e-05	10|240|26|3527	PF00071;PF00611;PF00612;PF02181;PF02214;PF06367;PF06371;PF07653;PF12796;PF13499
Group	GO:0009648	photoperiodism	3	7.14	6.60e-06	3.47e-05	6|240|9|3527	PF00076;PF00098;PF00249;PF00400;PF00989;PF08447
Group	GO:0016339	calcium-dependent cell-cell adhesion	3	7.14	6.60e-06	3.47e-05	6|240|9|3527	PF00028;PF00122;PF00689;PF00690;PF00702;PF02210
Group	GO:0008542	visual learning	3	6.75	7.47e-06	3.88e-05	7|240|13|3527	PF00014;PF00122;PF00689;PF00690;PF00702;PF02177;PF12924
Group	GO:0045822	negative regulation of heart contraction	3	7.45	7.95e-06	4.11e-05	5|240|6|3527	PF00122;PF00169;PF00689;PF00690;PF00702
Group	GO:0007254	JNK cascade	3	6.36	9.87e-06	4.97e-05	8|240|18|3527	PF00049;PF00240;PF00625;PF00640;PF00780;PF00786;PF01843;PF07653
Group	GO:0048840	otolith development	3	7.40	2.09e-05	9.85e-05	4|240|4|3527	PF00122;PF00689;PF00690;PF00702
Group	GO:0032468	Golgi calcium ion homeostasis	3	7.40	2.09e-05	9.85e-05	4|240|4|3527	PF00122;PF00689;PF00690;PF00702
Group	GO:0032472	Golgi calcium ion transport	3	7.40	2.09e-05	9.85e-05	4|240|4|3527	PF00122;PF00689;PF00690;PF00702
Group	GO:0035147	branch fusion, open tracheal system	3	6.80	2.63e-05	1.22e-04	5|240|7|3527	PF00435;PF00625;PF07653;PF08447;PF13855
Group	GO:0048640	negative regulation of developmental growth	3	6.30	3.23e-05	1.42e-04	6|240|11|3527	PF00019;PF00611;PF00622;PF00688;PF01403;PF02210
Group	GO:0002026	regulation of the force of heart contraction	3	6.30	3.23e-05	1.42e-04	6|240|11|3527	PF00122;PF00169;PF00689;PF00690;PF00702;PF01699
Group	GO:0032321	positive regulation of Rho GTPase activity	3	6.30	3.23e-05	1.42e-04	6|240|11|3527	PF00041;PF00611;PF00612;PF01404;PF06920;PF14429
Group	GO:0042384	cilium assembly	3	5.71	3.83e-05	1.67e-04	8|240|21|3527	PF00028;PF00225;PF00400;PF00581;PF01833;PF03133;PF07719;PF13414
Group	GO:0040023	establishment of nucleus localization	3	5.71	3.83e-05	1.67e-04	8|240|21|3527	PF00130;PF00435;PF00780;PF07728;PF08393;PF12774;PF12775;PF12780
Group	GO:0042462	eye photoreceptor cell development	3	5.88	4.17e-05	1.80e-04	7|240|16|3527	PF00096;PF00415;PF00612;PF00651;PF02210;PF03607;PF10409
Group	GO:0060491	regulation of cell projection assembly	3	5.52	5.67e-05	2.36e-04	8|240|22|3527	PF00071;PF00130;PF00612;PF00786;PF02181;PF06367;PF06371;PF12796
Group	GO:0006275	regulation of DNA replication	3	5.34	5.92e-05	2.46e-04	9|240|28|3527	PF00019;PF00134;PF00225;PF00341;PF00688;PF01336;PF12171;PF12756;PF12895
Group	GO:0036058	filtration diaphragm assembly	3	6.26	6.62e-05	2.69e-04	5|240|8|3527	PF00041;PF00102;PF00625;PF07653;PF07679
Group	GO:0010717	regulation of epithelial to mesenchymal transition	3	6.26	6.62e-05	2.69e-04	5|240|8|3527	PF00019;PF00514;PF00688;PF01404;PF03165
Group	GO:0010594	regulation of endothelial cell migration	3	6.26	6.62e-05	2.69e-04	5|240|8|3527	PF00019;PF00102;PF00130;PF00341;PF00688
Group	GO:0033135	regulation of peptidyl-serine phosphorylation	3	6.26	6.62e-05	2.69e-04	5|240|8|3527	PF00019;PF00169;PF00452;PF00688;PF00786
Group	GO:0051238	sequestering of metal ion	3	6.50	9.91e-05	3.85e-04	4|240|5|3527	PF00122;PF00689;PF00690;PF00702
Group	GO:0055071	manganese ion homeostasis	3	6.50	9.91e-05	3.85e-04	4|240|5|3527	PF00122;PF00689;PF00690;PF00702
Group	GO:0018209	peptidyl-serine modification	3	5.42	1.03e-04	3.94e-04	7|240|18|3527	PF00130;PF00169;PF00341;PF01462;PF02210;PF03062;PF13855
Group	GO:0022405	hair cycle process	3	5.42	1.03e-04	3.94e-04	7|240|18|3527	PF00019;PF00688;PF00757;PF01030;PF01391;PF02210;PF07679
Group	GO:0051302	regulation of cell division	3	5.42	1.03e-04	3.94e-04	7|240|18|3527	PF00071;PF00130;PF00225;PF00400;PF00514;PF00621;PF07679
Group	GO:0007520	myoblast fusion	3	5.64	1.07e-04	4.01e-04	6|240|13|3527	PF00041;PF01369;PF06920;PF07679;PF12796;PF13414
Group	GO:0007179	transforming growth factor beta receptor signaling pathway	3	5.64	1.07e-04	4.01e-04	6|240|13|3527	PF00106;PF00341;PF00683;PF01064;PF07645;PF12874
Group	GO:0035265	organ growth	3	5.64	1.07e-04	4.01e-04	6|240|13|3527	PF00019;PF00688;PF02037;PF07679;PF12796;PF14324
Group	GO:0050885	neuromuscular process controlling balance	3	5.64	1.07e-04	4.01e-04	6|240|13|3527	PF00014;PF00028;PF02177;PF07653;PF12796;PF12924
Group	GO:0017145	stem cell division	3	5.18	1.16e-04	4.30e-04	8|240|24|3527	PF00019;PF00076;PF00096;PF00130;PF00640;PF00688;PF01064;PF03165
Group	GO:0001751	compound eye photoreceptor cell differentiation	3	5.81	1.41e-04	5.06e-04	5|240|9|3527	PF00071;PF00096;PF00612;PF00651;PF10409
Group	GO:0006611	protein export from nucleus	3	5.81	1.41e-04	5.06e-04	5|240|9|3527	PF00019;PF00688;PF03810;PF08389;PF13499
Group	GO:0045186	zonula adherens assembly	3	5.81	1.41e-04	5.06e-04	5|240|9|3527	PF00130;PF00169;PF00435;PF02828;PF07653
Group	GO:0007176	regulation of epidermal growth factor-activated receptor activity	3	5.81	1.41e-04	5.06e-04	5|240|9|3527	PF00014;PF01585;PF02177;PF07525;PF12924
Group	GO:0060571	morphogenesis of an epithelial fold	3	5.81	1.41e-04	5.06e-04	5|240|9|3527	PF00130;PF00621;PF00757;PF01030;PF07679
Group	GO:0048009	insulin-like growth factor receptor signaling pathway	3	5.81	1.41e-04	5.06e-04	5|240|9|3527	PF00049;PF00169;PF00757;PF01030;PF02145
Group	GO:0001666	response to hypoxia	3	4.73	1.47e-04	5.27e-04	11|240|45|3527	PF00019;PF00045;PF00341;PF00413;PF00643;PF00688;PF00989;PF02145;PF02931;PF08447;PF13716
Group	GO:0007050	cell cycle arrest	3	5.21	1.54e-04	5.46e-04	7|240|19|3527	PF00019;PF00023;PF00350;PF00397;PF00640;PF00688;PF07645
Group	GO:0032506	cytokinetic process	3	5.21	1.54e-04	5.46e-04	7|240|19|3527	PF00071;PF00169;PF00225;PF00621;PF02181;PF06367;PF06371
Group	GO:0008358	maternal determination of anterior/posterior axis, embryo	3	5.37	1.76e-04	6.03e-04	6|240|14|3527	PF00076;PF00622;PF00651;PF01064;PF07525;PF13091
Group	GO:0002118	aggressive behavior	3	5.37	1.76e-04	6.03e-04	6|240|14|3527	PF00076;PF00096;PF00651;PF00970;PF01369;PF13855
Group	GO:0034332	adherens junction organization	3	5.37	1.76e-04	6.03e-04	6|240|14|3527	PF00028;PF00514;PF00625;PF00640;PF07653;PF07679
Group	GO:0006885	regulation of pH	3	5.02	2.23e-04	7.41e-04	7|240|20|3527	PF00122;PF00400;PF00689;PF00690;PF00702;PF01496;PF13499
Group	GO:0045667	regulation of osteoblast differentiation	3	5.02	2.23e-04	7.41e-04	7|240|20|3527	PF00019;PF00093;PF00514;PF00688;PF01064;PF03165;PF07645
Group	GO:0042036	negative regulation of cytokine biosynthetic process	3	5.43	2.66e-04	8.64e-04	5|240|10|3527	PF00019;PF00023;PF00076;PF00688;PF12796
Group	GO:0035010	encapsulation of foreign target	3	5.43	2.66e-04	8.64e-04	5|240|10|3527	PF00041;PF00071;PF00130;PF01404;PF10409
Group	GO:0051645	Golgi localization	3	5.43	2.66e-04	8.64e-04	5|240|10|3527	PF00388;PF00612;PF01843;PF09279;PF13499
Group	GO:0035001	dorsal trunk growth, open tracheal system	3	5.83	2.81e-04	9.04e-04	4|240|6|3527	PF00057;PF00625;PF02828;PF07653
Group	GO:0032856	activation of Ras GTPase activity	3	5.83	2.81e-04	9.04e-04	4|240|6|3527	PF00041;PF00169;PF01404;PF02145
Group	GO:0070167	regulation of biomineral tissue development	3	4.89	4.18e-04	1.29e-03	6|240|16|3527	PF00019;PF00594;PF00688;PF01064;PF02210;PF07645
Group	GO:0045444	fat cell differentiation	3	4.89	4.18e-04	1.29e-03	6|240|16|3527	PF00019;PF00249;PF00389;PF00688;PF01391;PF02826
Group	GO:0046331	lateral inhibition	3	4.89	4.18e-04	1.29e-03	6|240|16|3527	PF00130;PF00621;PF00625;PF01465;PF02828;PF07653
Group	GO:1901185	negative regulation of ERBB signaling pathway	3	4.89	4.18e-04	1.29e-03	6|240|16|3527	PF00041;PF01448;PF01585;PF07525;PF07679;PF13855
Group	GO:0001892	embryonic placenta development	3	4.67	4.36e-04	1.34e-03	7|240|22|3527	PF00169;PF00341;PF00757;PF00989;PF01030;PF07679;PF08447
Group	GO:0006582	melanin metabolic process	3	5.10	4.60e-04	1.40e-03	5|240|11|3527	PF00041;PF00071;PF00130;PF01404;PF10409
Group	GO:0060151	peroxisome localization	3	5.10	4.60e-04	1.40e-03	5|240|11|3527	PF00388;PF00612;PF01843;PF09279;PF13499
Group	GO:0007623	circadian rhythm	3	4.46	5.01e-04	1.51e-03	8|240|29|3527	PF00027;PF00076;PF00098;PF00249;PF00583;PF00989;PF08447;PF13716
Group	GO:0009826	unidimensional cell growth	3	4.51	5.91e-04	1.76e-03	7|240|23|3527	PF00071;PF00130;PF00621;PF00786;PF01064;PF01843;PF13855
Group	GO:0007173	epidermal growth factor receptor signaling pathway	3	4.51	5.91e-04	1.76e-03	7|240|23|3527	PF00019;PF00130;PF00169;PF00688;PF00757;PF01030;PF07645
Group	GO:0016525	negative regulation of angiogenesis	3	4.51	5.91e-04	1.76e-03	7|240|23|3527	PF00041;PF00090;PF00093;PF00102;PF00643;PF07645;PF12947
Group	GO:0030010	establishment of cell polarity	3	4.51	5.91e-04	1.76e-03	7|240|23|3527	PF00041;PF00130;PF00169;PF00400;PF00621;PF01369;PF01404
Group	GO:0070050	neuron homeostasis	3	5.29	6.22e-04	1.78e-03	4|240|7|3527	PF00041;PF07679;PF12796;PF13857
Group	GO:0051291	protein heterooligomerization	3	5.29	6.22e-04	1.78e-03	4|240|7|3527	PF00041;PF00757;PF01030;PF01391
Group	GO:0040035	hermaphrodite genitalia development	3	5.29	6.22e-04	1.78e-03	4|240|7|3527	PF00076;PF00125;PF00134;PF00400
Group	GO:0010770	positive regulation of cell morphogenesis involved in differentiation	3	5.29	6.22e-04	1.78e-03	4|240|7|3527	PF00019;PF00514;PF00688;PF03165
Group	GO:0032233	positive regulation of actin filament bundle assembly	3	5.29	6.22e-04	1.78e-03	4|240|7|3527	PF00041;PF00621;PF00786;PF01404
Group	GO:0006828	manganese ion transport	3	5.29	6.22e-04	1.78e-03	4|240|7|3527	PF00122;PF00689;PF00690;PF00702
Group	GO:0007309	oocyte axis specification	3	4.68	6.10e-04	1.78e-03	6|240|17|3527	PF00076;PF00130;PF00622;PF00651;PF07525;PF13091
Group	GO:0010923	negative regulation of phosphatase activity	3	4.68	6.10e-04	1.78e-03	6|240|17|3527	PF00028;PF00076;PF00254;PF00625;PF07653;PF13499
Group	GO:0033205	cell cycle cytokinesis	3	4.68	6.10e-04	1.78e-03	6|240|17|3527	PF00071;PF00225;PF00514;PF00612;PF00621;PF02181
Group	GO:0019722	calcium-mediated signaling	3	4.80	7.46e-04	2.09e-03	5|240|12|3527	PF00122;PF00689;PF00690;PF00702;PF13499
Group	GO:0001935	endothelial cell proliferation	3	4.80	7.46e-04	2.09e-03	5|240|12|3527	PF00019;PF00625;PF00688;PF05485;PF07653
Group	GO:0007088	regulation of mitosis	3	4.36	7.86e-04	2.19e-03	7|240|24|3527	PF00019;PF00341;PF00688;PF02148;PF07679;PF12895;PF13414
Group	GO:0045807	positive regulation of endocytosis	3	4.48	8.63e-04	2.38e-03	6|240|18|3527	PF00341;PF00397;PF00400;PF00594;PF01391;PF02210
Group	GO:0007435	salivary gland morphogenesis	3	4.48	8.63e-04	2.38e-03	6|240|18|3527	PF00102;PF00514;PF01391;PF01403;PF07679;PF10409
Group	GO:0006029	proteoglycan metabolic process	3	4.48	8.63e-04	2.38e-03	6|240|18|3527	PF00049;PF01462;PF02210;PF02709;PF13733;PF13855
Group	GO:0006984	ER-nucleus signaling pathway	3	4.22	1.03e-03	2.80e-03	7|240|25|3527	PF00049;PF00122;PF00226;PF00400;PF00689;PF00690;PF00702
Group	GO:0051048	negative regulation of secretion	3	4.22	1.03e-03	2.80e-03	7|240|25|3527	PF00019;PF00622;PF00688;PF01064;PF01833;PF04055;PF13765
Group	GO:0016197	endosomal transport	3	4.11	1.03e-03	2.80e-03	8|240|32|3527	PF00025;PF00071;PF00179;PF00350;PF00397;PF02893;PF12763;PF13385
Group	GO:0060761	negative regulation of response to cytokine stimulus	3	4.86	1.18e-03	2.95e-03	4|240|8|3527	PF00041;PF00102;PF01391;PF02210
Group	GO:0050772	positive regulation of axonogenesis	3	4.86	1.18e-03	2.95e-03	4|240|8|3527	PF01403;PF01437;PF07679;PF13855
Group	GO:0000186	activation of MAPKK activity	3	4.86	1.18e-03	2.95e-03	4|240|8|3527	PF00019;PF00688;PF00780;PF07653
Group	GO:0051492	regulation of stress fiber assembly	3	4.86	1.18e-03	2.95e-03	4|240|8|3527	PF00041;PF00621;PF00786;PF01404
Group	GO:0060997	dendritic spine morphogenesis	3	4.86	1.18e-03	2.95e-03	4|240|8|3527	PF00041;PF01404;PF07653;PF12796
Group	GO:0034121	regulation of toll-like receptor signaling pathway	3	4.86	1.18e-03	2.95e-03	4|240|8|3527	PF00041;PF04055;PF07679;PF12796
Group	GO:0045196	establishment or maintenance of neuroblast polarity	3	4.86	1.18e-03	2.95e-03	4|240|8|3527	PF00130;PF00625;PF02828;PF07653
Group	GO:0016332	establishment or maintenance of polarity of embryonic epithelium	3	4.86	1.18e-03	2.95e-03	4|240|8|3527	PF00130;PF00625;PF02828;PF07653
Group	GO:0050918	positive chemotaxis	3	4.86	1.18e-03	2.95e-03	4|240|8|3527	PF00019;PF00341;PF00688;PF02145
Group	GO:0060972	left/right pattern formation	3	4.86	1.18e-03	2.95e-03	4|240|8|3527	PF00400;PF00612;PF12796;PF13857
Group	GO:0030703	eggshell formation	3	4.86	1.18e-03	2.95e-03	4|240|8|3527	PF00028;PF00622;PF01064;PF07525
Group	GO:0009624	response to nematode	3	4.86	1.18e-03	2.95e-03	4|240|8|3527	PF00122;PF00689;PF00690;PF00702
Group	GO:0050852	T cell receptor signaling pathway	3	4.54	1.15e-03	2.95e-03	5|240|13|3527	PF00041;PF00388;PF00625;PF00969;PF09279
Group	GO:0051322	anaphase	3	4.54	1.15e-03	2.95e-03	5|240|13|3527	PF00225;PF00651;PF02148;PF07707;PF13964
Group	GO:0072002	Malpighian tubule development	3	4.54	1.15e-03	2.95e-03	5|240|13|3527	PF00621;PF01064;PF07679;PF12796;PF13414
Group	GO:0042476	odontogenesis	3	4.30	1.19e-03	2.95e-03	6|240|19|3527	PF00019;PF00096;PF00688;PF01064;PF01391;PF07679
Group	GO:0009636	response to toxin	3	4.30	1.19e-03	2.95e-03	6|240|19|3527	PF00122;PF00452;PF00702;PF00989;PF02931;PF08447
Group	GO:0061136	regulation of proteasomal protein catabolic process	3	4.30	1.19e-03	2.95e-03	6|240|19|3527	PF00240;PF00400;PF00778;PF00789;PF02148;PF13414
Group	GO:0021536	diencephalon development	3	4.30	1.19e-03	2.95e-03	6|240|19|3527	PF00019;PF00096;PF00249;PF00688;PF01064;PF07679
Group	GO:0045931	positive regulation of mitotic cell cycle	3	4.13	1.61e-03	3.91e-03	6|240|20|3527	PF00014;PF00096;PF00130;PF01448;PF02177;PF12924
Group	GO:0048771	tissue remodeling	3	4.30	1.68e-03	4.03e-03	5|240|14|3527	PF00049;PF00082;PF00452;PF00688;PF01064
Group	GO:0007349	cellularization	3	4.30	1.68e-03	4.03e-03	5|240|14|3527	PF00071;PF00130;PF00350;PF00612;PF00621
Group	GO:0051588	regulation of neurotransmitter transport	3	4.30	1.68e-03	4.03e-03	5|240|14|3527	PF00019;PF00071;PF01833;PF02214;PF02931
Group	GO:1901216	positive regulation of neuron death	3	4.30	1.68e-03	4.03e-03	5|240|14|3527	PF00041;PF00452;PF01404;PF07679;PF13716
Group	GO:0007266	Rho protein signal transduction	3	4.30	1.68e-03	4.03e-03	5|240|14|3527	PF00169;PF00435;PF00612;PF00621;PF00651
Group	GO:0060968	regulation of gene silencing	3	4.30	1.68e-03	4.03e-03	5|240|14|3527	PF00076;PF00096;PF00651;PF01448;PF08210
Group	GO:0051092	positive regulation of NF-kappaB transcription factor activity	3	3.96	1.69e-03	4.03e-03	7|240|27|3527	PF00023;PF00130;PF00169;PF00621;PF00899;PF12796;PF13855
Group	GO:0001964	startle response	3	4.49	2.01e-03	4.62e-03	4|240|9|3527	PF00028;PF00096;PF00651;PF02931
Group	GO:0002040	sprouting angiogenesis	3	4.49	2.01e-03	4.62e-03	4|240|9|3527	PF00019;PF00341;PF00688;PF12796
Group	GO:0050806	positive regulation of synaptic transmission	3	4.49	2.01e-03	4.62e-03	4|240|9|3527	PF01699;PF02210;PF07679;PF13855
Group	GO:0007032	endosome organization	3	4.49	2.01e-03	4.62e-03	4|240|9|3527	PF00071;PF00169;PF00179;PF01496
Group	GO:0060428	lung epithelium development	3	4.49	2.01e-03	4.62e-03	4|240|9|3527	PF00049;PF00640;PF03165;PF07679
Group	GO:0043954	cellular component maintenance	3	4.49	2.01e-03	4.62e-03	4|240|9|3527	PF00169;PF00514;PF03607;PF13414
Group	GO:0036294	cellular response to decreased oxygen levels	3	4.49	2.01e-03	4.62e-03	4|240|9|3527	PF00023;PF00341;PF00989;PF08447
Group	GO:0006878	cellular copper ion homeostasis	3	4.49	2.01e-03	4.62e-03	4|240|9|3527	PF00014;PF00702;PF02177;PF12924
Group	GO:0001569	patterning of blood vessels	3	4.49	2.01e-03	4.62e-03	4|240|9|3527	PF00090;PF00341;PF01403;PF01437
Group	GO:0010821	regulation of mitochondrion organization	3	4.49	2.01e-03	4.62e-03	4|240|9|3527	PF00049;PF00169;PF00452;PF12906
Group	GO:0030833	regulation of actin filament polymerization	3	3.97	2.12e-03	4.81e-03	6|240|21|3527	PF00071;PF00130;PF00241;PF00786;PF02181;PF07653
Group	GO:0000209	protein polyubiquitination	3	3.97	2.12e-03	4.81e-03	6|240|21|3527	PF00179;PF01485;PF02825;PF07719;PF12895;PF13414
Group	GO:0007093	mitotic cell cycle checkpoint	3	3.84	2.13e-03	4.81e-03	7|240|28|3527	PF00019;PF00134;PF00452;PF00688;PF02037;PF12796;PF14324
Group	GO:0030522	intracellular receptor mediated signaling pathway	3	3.84	2.13e-03	4.81e-03	7|240|28|3527	PF00076;PF00226;PF00643;PF00684;PF00989;PF08447;PF13426
Group	GO:0042552	myelination	3	3.84	2.13e-03	4.81e-03	7|240|28|3527	PF00041;PF00169;PF00612;PF01421;PF02023;PF07679;PF13716
Group	GO:0051965	positive regulation of synapse assembly	3	4.09	2.39e-03	5.26e-03	5|240|15|3527	PF00041;PF00621;PF01064;PF01404;PF03165
Group	GO:0010827	regulation of glucose transport	3	4.09	2.39e-03	5.26e-03	5|240|15|3527	PF00049;PF00130;PF00169;PF01391;PF12796
Group	GO:0060840	artery development	3	4.09	2.39e-03	5.26e-03	5|240|15|3527	PF00019;PF00106;PF00688;PF01064;PF13716
Group	GO:0051340	regulation of ligase activity	3	4.09	2.39e-03	5.26e-03	5|240|15|3527	PF00023;PF00179;PF00240;PF00400;PF02148
Group	GO:0043112	receptor metabolic process	3	4.09	2.39e-03	5.26e-03	5|240|15|3527	PF00019;PF00082;PF00169;PF00397;PF00688
Group	GO:0032273	positive regulation of protein polymerization	3	3.82	2.75e-03	5.99e-03	6|240|22|3527	PF00025;PF00071;PF00611;PF00786;PF02181;PF07653
Group	GO:0007416	synapse assembly	3	3.82	2.75e-03	5.99e-03	6|240|22|3527	PF00028;PF00130;PF02177;PF02210;PF07653;PF12924
Group	GO:0060021	palate development	3	3.82	2.75e-03	5.99e-03	6|240|22|3527	PF00019;PF00096;PF00688;PF01064;PF03165;PF07719
Group	GO:0018108	peptidyl-tyrosine phosphorylation	3	3.82	2.75e-03	5.99e-03	6|240|22|3527	PF00041;PF00341;PF00611;PF01404;PF07645;PF07679
Group	GO:0070206	protein trimerization	3	4.73	2.81e-03	6.00e-03	3|240|5|3527	PF00622;PF00643;PF01391
Group	GO:0045161	neuronal ion channel clustering	3	4.73	2.81e-03	6.00e-03	3|240|5|3527	PF00041;PF00435;PF07679
Group	GO:0060363	cranial suture morphogenesis	3	4.73	2.81e-03	6.00e-03	3|240|5|3527	PF00019;PF00688;PF07679
Group	GO:0048036	central complex development	3	4.73	2.81e-03	6.00e-03	3|240|5|3527	PF00041;PF00102;PF07679
Group	GO:0022416	chaeta development	3	4.73	2.81e-03	6.00e-03	3|240|5|3527	PF00076;PF00625;PF07653
Group	GO:0090109	regulation of cell-substrate junction assembly	3	4.17	3.17e-03	6.60e-03	4|240|10|3527	PF00041;PF00341;PF01404;PF10409
Group	GO:0051567	histone H3-K9 methylation	3	4.17	3.17e-03	6.60e-03	4|240|10|3527	PF00134;PF00225;PF12796;PF13857
Group	GO:0051784	negative regulation of nuclear division	3	4.17	3.17e-03	6.60e-03	4|240|10|3527	PF00019;PF00688;PF02148;PF07679
Group	GO:0021954	central nervous system neuron development	3	4.17	3.17e-03	6.60e-03	4|240|10|3527	PF00041;PF01404;PF03165;PF03607
Group	GO:0051057	positive regulation of small GTPase mediated signal transduction	3	4.17	3.17e-03	6.60e-03	4|240|10|3527	PF00071;PF00130;PF00618;PF13855
Group	GO:0060026	convergent extension	3	4.17	3.17e-03	6.60e-03	4|240|10|3527	PF00610;PF00778;PF02377;PF06297
Group	GO:0045778	positive regulation of ossification	3	4.17	3.17e-03	6.60e-03	4|240|10|3527	PF00019;PF00688;PF01064;PF07645
Group	GO:0008624	induction of apoptosis by extracellular signals	3	4.17	3.17e-03	6.60e-03	4|240|10|3527	PF00169;PF00621;PF01335;PF07653
Group	GO:0010464	regulation of mesenchymal cell proliferation	3	3.89	3.28e-03	6.74e-03	5|240|16|3527	PF00019;PF00341;PF00688;PF03165;PF07679
Group	GO:0042752	regulation of circadian rhythm	3	3.89	3.28e-03	6.74e-03	5|240|16|3527	PF00027;PF00076;PF00098;PF00989;PF08447
Group	GO:0008203	cholesterol metabolic process	3	3.89	3.28e-03	6.74e-03	5|240|16|3527	PF00014;PF00057;PF02177;PF07645;PF12924
Group	GO:0035150	regulation of tube size	3	3.89	3.28e-03	6.74e-03	5|240|16|3527	PF00057;PF00625;PF02828;PF07653;PF13903
Group	GO:0006937	regulation of muscle contraction	3	3.89	3.28e-03	6.74e-03	5|240|16|3527	PF00122;PF00689;PF00690;PF00702;PF02931
Group	GO:0048488	synaptic vesicle endocytosis	3	3.89	3.28e-03	6.74e-03	5|240|16|3527	PF00025;PF00071;PF01217;PF01417;PF12763
Group	GO:0030336	negative regulation of cell migration	3	3.68	3.52e-03	7.17e-03	6|240|23|3527	PF00019;PF00102;PF00688;PF01391;PF10409;PF13855
Group	GO:0042157	lipoprotein metabolic process	3	3.68	3.52e-03	7.17e-03	6|240|23|3527	PF00025;PF00057;PF03062;PF07645;PF10277;PF12796
Group	GO:0006818	hydrogen transport	3	3.71	4.40e-03	8.86e-03	5|240|17|3527	PF00122;PF00153;PF00690;PF00702;PF01496
Group	GO:0045732	positive regulation of protein catabolic process	3	3.71	4.40e-03	8.86e-03	5|240|17|3527	PF00397;PF00400;PF00514;PF00778;PF07525
Group	GO:0008277	regulation of G-protein coupled receptor protein signaling pathway	3	3.55	4.43e-03	8.86e-03	6|240|24|3527	PF00169;PF00388;PF00610;PF02148;PF09279;PF13857
Group	GO:0007565	female pregnancy	3	3.55	4.43e-03	8.86e-03	6|240|24|3527	PF00045;PF00053;PF00055;PF00106;PF00413;PF01335
Group	GO:0050796	regulation of insulin secretion	3	3.55	4.43e-03	8.86e-03	6|240|24|3527	PF00019;PF00027;PF00688;PF00969;PF01064;PF02214
Group	GO:0006378	mRNA polyadenylation	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF00014;PF02177;PF12874;PF12924
Group	GO:0060438	trachea development	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF00057;PF00625;PF01391;PF07653
Group	GO:0001959	regulation of cytokine-mediated signaling pathway	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF00041;PF00102;PF01391;PF02210
Group	GO:0001938	positive regulation of endothelial cell proliferation	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF00019;PF00130;PF00341;PF00688
Group	GO:0017156	calcium ion-dependent exocytosis	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF00027;PF00610;PF00618;PF02931
Group	GO:0048730	epidermis morphogenesis	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF00019;PF00688;PF01843;PF07679
Group	GO:1900077	negative regulation of cellular response to insulin stimulus	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF00102;PF00130;PF00169;PF10409
Group	GO:0009950	dorsal/ventral axis specification	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF00057;PF00076;PF00778;PF03165
Group	GO:0008586	imaginal disc-derived wing vein morphogenesis	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF00397;PF00612;PF01448;PF07645
Group	GO:0050805	negative regulation of synaptic transmission	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF01391;PF01699;PF12796;PF13857
Group	GO:0007044	cell-substrate junction assembly	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF00052;PF00053;PF00055;PF01391
Group	GO:0090192	regulation of glomerulus development	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF00019;PF00341;PF00688;PF01391
Group	GO:0090114	COPII-coated vesicle budding	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF00400;PF00651;PF04810;PF07707
Group	GO:0030032	lamellipodium assembly	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF00041;PF00102;PF00169;PF00621
Group	GO:0035020	regulation of Rac protein signal transduction	3	3.90	4.71e-03	9.10e-03	4|240|11|3527	PF00041;PF00071;PF01404;PF07679
Group	GO:0090068	positive regulation of cell cycle process	3	3.40	4.78e-03	9.22e-03	7|240|32|3527	PF00071;PF00076;PF00130;PF00134;PF00240;PF00341;PF01448
Group	GO:0022028	tangential migration from the subventricular zone to the olfactory bulb	3	4.20	5.34e-03	9.96e-03	3|240|6|3527	PF01462;PF02210;PF13855
Group	GO:0032878	regulation of establishment or maintenance of cell polarity	3	4.20	5.34e-03	9.96e-03	3|240|6|3527	PF00049;PF00071;PF00400
Group	GO:0060119	inner ear receptor cell development	3	4.20	5.34e-03	9.96e-03	3|240|6|3527	PF00028;PF00122;PF00690
Group	GO:0045838	positive regulation of membrane potential	3	4.20	5.34e-03	9.96e-03	3|240|6|3527	PF02210;PF07653;PF12796
Group	GO:0045806	negative regulation of endocytosis	3	4.20	5.34e-03	9.96e-03	3|240|6|3527	PF00400;PF00611;PF01391
Group	GO:0002467	germinal center formation	3	4.20	5.34e-03	9.96e-03	3|240|6|3527	PF00023;PF00651;PF12796
Group	GO:0038007	netrin-activated signaling pathway	3	4.20	5.34e-03	9.96e-03	3|240|6|3527	PF00041;PF00090;PF07679
Group	GO:0061099	negative regulation of protein tyrosine kinase activity	3	4.20	5.34e-03	9.96e-03	3|240|6|3527	PF00400;PF01585;PF07525
Group	GO:0034381	plasma lipoprotein particle clearance	3	4.20	5.34e-03	9.96e-03	3|240|6|3527	PF00057;PF01391;PF07645
Group	GO:0043555	regulation of translation in response to stress	3	4.20	5.34e-03	9.96e-03	3|240|6|3527	PF00076;PF00098;PF05773
Group	GO:0048669	collateral sprouting in absence of injury	3	4.20	5.34e-03	9.96e-03	3|240|6|3527	PF00014;PF02177;PF12924
Group	GO:0018095	protein polyglutamylation	4	7.40	2.09e-05	9.85e-05	4|240|4|3527	PF00581;PF03133;PF07719;PF13414
Group	GO:0010256	endomembrane system organization	4	6.41	3.11e-04	9.93e-04	3|240|3|3527	PF01369;PF09324;PF12783
Group	GO:0060971	embryonic heart tube left/right pattern formation	4	6.41	3.11e-04	9.93e-04	3|240|3|3527	PF00612;PF12796;PF13857
Group	GO:0070979	protein K11-linked ubiquitination	4	5.29	6.22e-04	1.78e-03	4|240|7|3527	PF00179;PF07719;PF12895;PF13414
Group	GO:0007183	SMAD protein complex assembly	4	5.42	1.18e-03	2.95e-03	3|240|4|3527	PF00019;PF00688;PF03165
Group	GO:0010862	positive regulation of pathway-restricted SMAD protein phosphorylation	4	5.42	1.18e-03	2.95e-03	3|240|4|3527	PF00019;PF00688;PF01064
Group	GO:0033138	positive regulation of peptidyl-serine phosphorylation	4	5.42	1.18e-03	2.95e-03	3|240|4|3527	PF00019;PF00688;PF00786
Group	GO:0008053	mitochondrial fusion	4	5.42	1.18e-03	2.95e-03	3|240|4|3527	PF00350;PF00452;PF13091
Group	GO:0031145	anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process	4	5.42	1.18e-03	2.95e-03	3|240|4|3527	PF00179;PF12895;PF13414
Group	GO:0034122	negative regulation of toll-like receptor signaling pathway	4	5.42	1.18e-03	2.95e-03	3|240|4|3527	PF00041;PF07679;PF12796
Group	GO:0040010	positive regulation of growth rate	4	4.73	2.81e-03	6.00e-03	3|240|5|3527	PF00125;PF00133;PF00989
Group	GO:0045648	positive regulation of erythrocyte differentiation	4	4.73	2.81e-03	6.00e-03	3|240|5|3527	PF00019;PF00688;PF12796
Group	GO:0001974	blood vessel remodeling	4	4.20	5.34e-03	9.96e-03	3|240|6|3527	PF00049;PF00452;PF01064
